US20110098809A1 - Ocular Implant System and Method - Google Patents
Ocular Implant System and Method Download PDFInfo
- Publication number
- US20110098809A1 US20110098809A1 US12/911,451 US91145110A US2011098809A1 US 20110098809 A1 US20110098809 A1 US 20110098809A1 US 91145110 A US91145110 A US 91145110A US 2011098809 A1 US2011098809 A1 US 2011098809A1
- Authority
- US
- United States
- Prior art keywords
- canal
- schlemm
- eye
- channel
- cannula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *CCC1CCCC1 Chemical compound *CCC1CCCC1 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Definitions
- glaucoma is now the leading cause of irreversible blindness worldwide and the second leading cause of blindness, behind cataract, in the world.
- NASH National Eye Institute
- Glaucoma researchers have found a strong correlation between high intraocular pressure and glaucoma.
- shunts were implanted to direct aqueous humor from the anterior chamber to the extraocular vein (Lee and Scheppens, “Aqueous-venous shunt and intraocular pressure,” Investigative Ophthalmology (February 1966)).
- Other early glaucoma treatment implants led from the anterior chamber to a sub-conjunctival bleb (e.g., U.S. Pat. No. 4,968,296 and U.S. Pat. No. 5,180,362).
- glaucoma treatment devices that are disposed partially or completely within Schlemm's canal have been described. Examples of such devices may be found, e.g., in U.S. Pat. No. 7,740,604; US Patent Publ. No. 2009/0082860; US Patent Publ. No. 2009/0227934; US Patent Publ. No. 2009/0132040; US Patent Publ. No. 2010/0121342; US Patent Publ. No. 2006/0195187; and U.S. application Ser. No. 12/833,863.
- the Schlemm's canal of a patient suffering from glaucoma has lost some or all of its natural functionality. Due to the abnormal pressures caused by glaucoma, Schlemm's canal and related tissues may have lost the ability to move. In some patients, these conditions may result in the collapse and subsequent closure of part or all of Schlemm's canal. When this is the case, portions of the wall of Schlemm's canal may be pushed closed and may not be allowed to rebound to an open shape. Over time, the collapsed wall of Schlemm's canal may adhere to itself causing the canal to become compartmentalized.
- One aspect of the invention provides an ocular implant and delivery system having a channel tool (such as a torque tube or coil) adapted to extend through at least a portion of Schlemm's canal of a human eye and to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant; an ocular implant adapted to be disposed within Schlemm's canal of a human eye; and a cannula comprising a distal opening adapted to deliver the channel tool and the ocular implant into Schlemm's canal of the eye.
- the channel tool is further adapted to open a channel within the Schlemm's canal portion.
- Some embodiments of the invention also have a proximal control adapted to be operated from exterior to the eye to move the channel opening tool and the ocular implant when the distal opening of the cannula is within the eye.
- the channel opening tool may be configured to be disposed within the ocular implant and to move with respect to the ocular implant.
- the system includes a fluid and a fluid injection mechanism adapted to inject the fluid (such as, e.g., a dilatation agent adapted to dilate tissue) into Schlemm's canal of the eye through the cannula.
- the channel opening tool has a fluid lumen and the fluid injection mechanism is adapted to inject fluid through the channel opening tool fluid lumen.
- the channel opening tool may have a distal opening communicating with the fluid lumen and/or a liner tube surrounding the fluid lumen.
- the fluid injection mechanism has a piston disposed in a cylinder.
- the fluid injection mechanism may also include an injection tube extending from an outlet of the cylinder to the handle.
- Another aspect of the invention provides a method of treating glaucoma in a human eye including the steps of: inserting a distal exit port of a cannula at least partially into Schlemm's canal of the eye; delivering a channel tool through the cannula into Schlemm's canal; delivering an ocular implant through the cannula into Schlemm's canal; and removing the channel tool and the cannula from the eye while leaving the ocular implant in place within Schlemm's canal.
- the method includes the step of delivering a dye through the channel tool and observing the behavior of the dye to identify the location of obstructions within Schlemm's canal.
- the method includes the step of opening a channel in Schlemm's canal with the channel tool.
- the step of opening a channel may include the step of moving the channel tool within Schlemm's canal.
- the step of opening a channel may include the step of delivering a fluid (such as a dilatation agent, a therapeutic agent and/or a dye) through the channel tool by, e.g., moving the fluid through an obstruction within Schlemm's canal to increase fluid communication between adjacent segments of Schlemm's canal.
- a fluid such as a dilatation agent, a therapeutic agent and/or a dye
- the delivering steps include the step of delivering the channel opening tool and the ocular implant without removing the distal tip of the cannula from the eye.
- Some embodiments of the method include the step of moving the channel opening tool and the ocular implant with respect to each other within Schlemm's canal.
- the delivering steps include the step of delivering the ocular implant over the channel opening tool.
- the inserting step includes the step of inserting the distal exit port of the cannula at least partially into Schlemm's canal of the eye through an ab interno approach. In other embodiments, the inserting step includes the step of inserting the distal exit port of the cannula at least partially into Schlemm's canal of the eye through an ab externo approach.
- an ocular implant and delivery system including a channel tool adapted to extend through at least a portion of Schlemm's canal of a human eye and to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant; a cannula comprising a distal opening adapted to deliver the channel tool and the ocular implant into Schlemm's canal of the eye; and a proximal control adapted to move the channel tool with respect to the cannula.
- Still another aspect of the invention provides a method of treating glaucoma in a human eye including the steps of inserting a distal exit port of a cannula at least partially into Schlemm's canal of the eye; delivering a channel tool through the cannula into Schlemm's canal using a proximal control; and removing the channel tool and the cannula from the eye while leaving the ocular implant in place within Schlemm's canal.
- FIG. 1 is a stylized representation of an exemplary medical procedure in accordance with this detailed description.
- FIGS. 2A and 2C are perspective views illustrating an ocular implant and delivery system and method according to an embodiment of this invention.
- FIG. 2B is an enlarged perspective view of a cannula and channel tool of the system shown in FIG. 2A .
- FIG. 3 is a stylized partial cross-sectional and partial plan view of an ocular implant and delivery system according to an embodiment of this invention.
- FIG. 4A is a partial cross-sectional view of a distal portion of a channel tool according to an embodiment of this invention.
- FIG. 4B is a partial cross-sectional view of a distal portion of a channel tool according to another embodiment of this invention.
- FIG. 5 is a partial cross-sectional view of a distal portion of a channel tool according to yet another embodiment of this invention.
- FIG. 6 is a stylized perspective view illustrating the anatomy of an eye.
- FIG. 7 is a stylized perspective view showing Schlemm's canal and an iris of the eye shown in the previous figure.
- FIG. 8 is an enlarged cross-sectional view further illustrating Schlemm's canal shown in the previous figure.
- FIG. 9 is a stylized perspective view of an eye in which a scleral flap has been formed.
- FIG. 10 is a stylized perspective view of the eye of FIG. 9 in which a second scleral flap has been formed.
- FIG. 11 is a stylized perspective view of the eye of FIGS. 9 and 10 in which openings have been made in Schlemm's canal.
- FIG. 12 is a stylized perspective view of the eye of FIGS. 9-11 showing a cannula proximate the eye.
- FIG. 13 is a stylized perspective view of the eye of FIGS. 9-12 showing the insertion of a distal tip of a cannula into Schlemm's canal.
- FIG. 14 is a stylized perspective view of the eye of FIGS. 9-13 showing a channel tool and ocular implant being advanced out of the cannula and into Schlemm's canal.
- FIG. 15 is a stylized perspective view of the eye of FIGS. 9-14 showing retraction of the channel tool from Schlemm's canal, leaving the ocular implant in Schlemm's canal.
- FIG. 16 is a stylized perspective view of the eye of FIGS. 9-15 showing removal of the cannula from the eye.
- FIG. 17 is a stylized perspective view of the eye of FIGS. 9-16 showing closing of the scleral flap.
- FIGS. 18A and 18B are stylized perspective views of eyes in which ocular implants have been placed in Schlemm's canal.
- FIG. 19A is a stylized perspective view of an eye in which an ocular implant has been placed with an inlet in the anterior chamber and the remainder of the device in Schlemm's canal.
- FIG. 19B is a stylized perspective view of an eye in which an ocular implant has been placed so that it lies entirely within Schlemm's canal.
- FIGS. 20A-D and 21 show details of a method of using the system of this invention.
- FIGS. 22A-F show details of a method of using the system of this invention.
- FIG. 23A is a perspective view of certain components of an ocular implant and delivery system according to an embodiment of this invention.
- FIG. 23B is a detail view of the distal end of the system shown in FIG. 23A .
- FIG. 24 is an elevational view of a cannula, push tube ocular plant of a system according to an embodiment of this invention.
- FIGS. 25A-B show details of the connection between the ocular implant and push tube shown in FIG. 24 .
- FIG. 1 is a stylized representation of an exemplary medical procedure in accordance with this detailed description.
- a physician is treating an eye 20 of a patient P using a therapy system 100 , such as an ocular implant and delivery system.
- a therapy system 100 such as an ocular implant and delivery system.
- the physician is holding a handle portion of therapy system 100 in his or her right hand RH.
- the physician's left hand (not shown) may be used to hold the handle H of a gonio lens 23 . It will be appreciated that some physician's may prefer holding the therapy system handle in the left hand and the gonio lens handle H in the right hand RH.
- the physician may view the interior of the anterior chamber using gonio lens 23 and a microscope 25 .
- Detail A of FIG. 1 is a stylized simulation of the image viewed by the physician.
- a distal portion of a cannula 102 is visible in Detail A.
- a shadow-like line indicates the location of Schlemm's canal SC which is lying under various tissue (e.g., the trabecular meshwork) that surround the anterior chamber.
- a distal opening 104 of cannula 102 is positioned near Schlemm's canal SC of eye 20 .
- distal opening 104 of cannula 102 is placed in fluid communication with Schlemm's canal SC.
- a device e.g., an implant or a delivery tool for an implant
- a device may be advanced through distal opening 104 and into Schlemm's canal SC.
- FIG. 2A is a perspective view further illustrating therapy system 100 and eye 20 shown in the previous figure.
- cannula 102 of therapy system 100 is shown extending through a cornea 40 of eye 20 .
- a distal portion of cannula 102 is disposed inside the anterior chamber defined by cornea 40 of eye 20 .
- cannula 102 is configured so that a distal opening 104 of cannula 102 can be placed in fluid communication with Schlemm's canal.
- a channel tool 126 is disposed in a lumen defined by cannula 102 .
- Therapy system 100 includes a mechanism that is capable of advancing and retracting the channel tool along the length of cannula 102 .
- the channel tool 126 may be placed in Schlemm's canal of eye 20 by advancing the channel tool through distal opening 104 of cannula 102 while distal opening 104 is in fluid communication with Schlemm's canal.
- FIG. 2B is an enlarged detail view further illustrating cannula 102 of therapy system 100 .
- channel tool 126 has been advanced through distal opening 104 of cannula 102 .
- Cannula 102 of FIG. 2B defines a passageway 124 that fluidly communicates with distal opening 104 .
- Channel tool 126 may be moved along passageway 124 and through distal opening 104 by therapy system 100 .
- Therapy system 100 includes a proximal control mechanism 101 disposed outside of the eye that is capable of performing this function.
- FIG. 2C is an enlarged perspective view further illustrating eye 20 shown in FIG. 2A .
- a cannula 102 of a therapy system 100 can be seen extending through cornea 40 of eye 20 so that a distal portion D of cannula 102 disposed in the anterior chamber AC of eye 20 .
- cannula 102 has been positioned so that distal port 104 of cannula 102 is in fluid communication with Schlemm's canal of eye 20 .
- a channel tool 126 of therapy system 100 has been advance through distal port 104 of cannula 102 and into Schlemm's canal of eye 20 .
- FIG. 3 is a stylized plan view illustrating an exemplary therapy system 1100 in accordance with this detailed description.
- the therapy system 1100 of FIG. 3 includes a channel tool 1152 , a cannula 1108 , and a fluid injection assembly 1162 .
- fluid injection assembly 1162 includes a syringe (i.e., a piston disposed in a cylinder) 1163 that is filled with fluid 1164 .
- Therapy system 1100 of FIG. 3 may be used, for example, to determine whether Schlemm's canal of an eye provides a suitable location for the delivery of an ocular implant and/or to open Schlemm's canal of the eye.
- Exemplary methods in accordance with this detailed description may include the step of advancing a distal portion of channel tool 1152 through the distal port 1109 of cannula 1108 into Schlemm's canal of an eye. If resistance is encountered as channel tool 1152 is advanced, the user is provided with an indication that Schlemm's canal is partially or completely blocked.
- the channel tool 1152 may be advanced through the blockage to open a channel in Schlemm's canal and/or to increase fluid communication between adjacent segments of Schlemm's canal.
- the channel tool may also used to inject fluid 1164 into Schlemm's canal to open the canal and/or to provide lubrication for further advancement of the channel tool into the canal.
- a physician may use channel tool 1152 to visually identify obstructions.
- channel tool 1152 may be used to inject a visualization enhancing fluid (e.g., a dye) into Schlemm's canal.
- a visualization enhancing fluid e.g., a dye
- the physician may observe the movement of that fluid within Schlemm's canal using a microscope and a gonio lens as shown in FIG. 1 .
- Therapy system 1100 may also be used to deliver an implant, such as an aqueous humor drainage device, into Schlemm's canal of the eye. When this is the case, the aqueous humor drainage device may be mounted on channel tool 1152 .
- channel tool 1152 is shown extending through a distal port 1109 of cannula 1108 .
- Cannula 1108 is coupled to a proximal control 1102 of therapy system 1100 .
- Proximal control 1102 includes a mechanism 1166 that is capable of advancing and retracting channel tool 1152 .
- mechanism 1166 is substantially disposed inside proximal control 1102 .
- channel tool 1152 includes a coiled cable.
- An injection tube 1156 extends from a fluid injection port 1168 in syringe 1163 through proximal control 1102 to deliver fluid 1164 to channel tool 1152 .
- Fluid 1164 that has exited channel tool 1152 is represented by a number of fluid drops in the stylized plan view of FIG. 3 .
- Fluid injection assembly 1162 includes a mechanism including a lever. The mechanism cooperates with syringe 1163 to dispense fluid (e.g., the drops shown in FIG. 3 ). In the exemplary embodiment of FIG. 3 , fluid injection assembly 1162 will dispense a controlled volume of fluid each time the lever is actuated.
- fluid injection assembly 1162 may employ a screw type ratcheting plunger which can dispense a controlled volume per click of the ratchet mechanism.
- fluid 1164 may comprise various materials without deviating from the spirit and scope of the present detailed description.
- fluids that may be suitable in some applications include water, saline, hyaluronic acid and/or viscoelastic.
- viscoelastic is sometimes used to describe various viscoelastic materials that are injected into the eye as part of a surgical procedure. Viscoelastics for use in ophthalmic surgery are commercially available from Bausch and Lomb Incorporated (Rochester, N.Y., U.S.A.) and Alcon, Incorporated (Hünenberg, Switzerland). Viscoelastics may comprise, for example, hyaluronic acid.
- Hyaluronic acid is a material that is naturally found in the vitreous humor that fills the posterior chamber of the eye. Accordingly, this material is well suited for use in ophthalmic surgery.
- Hyaluronic acid is also known as hyaluronan and hyaluronate.
- a loop 1172 is formed in injection tube 1156 .
- loop 1172 is sized to provide a level of travel necessary to advance the distal end channel tool 1152 through the entire length of Schlemm's canal.
- loop 1172 is disposed inside proximal control 1102 .
- FIG. 4A is a partial cross-sectional view showing a distal portion of an exemplary channel tool 1152 in accordance with this detailed description.
- channel tool 1152 includes a cable 1154 and a distal tip 1160 at the distal end of cable 1154 .
- Distal tip 1160 may be attached to cable 1154 , for example, by welding.
- Distal tip 1160 is rounded so as to be atraumatic.
- Distal tip 1160 has a tip lumen 1174 fluidly communicating with a distal opening 1170 .
- cable 1154 is formed as a helical coil (formed, e.g., from stainless steel, nitinol or other suitable material) having a plurality of filars 1176 forming a hollow tube-like structure.
- cable 1154 comprises a torque cable.
- Torque cables that may be suitable in some applications are commercially available from Fort Wayne Metals, Inc. (Fort Wayne, Ind., U.S.A) and Asahi Intecc Co. Ltd. (Nagoya, Aichi Prefecture, Japan).
- each filar 1176 has a generally helical shape.
- filars 1176 of cable 1154 define a cable lumen 1178 . Lubricity of the coil can be enhanced by the application of a surface coating (PTFE, heparin, etc.) which will further reduce potential trauma and facilitate smooth predictable advancement.
- a liner tube 1158 is disposed inside cable lumen 1178 .
- Liner tube 1158 may be formed, e.g., from polyimide and defines a liner lumen 1180 that fluidly communicates with tip lumen 1174 defined by distal tip 1160 .
- FIG. 4A includes a plurality of arrows representing fluid 1164 flowing through tip lumen 1174 of channel tool 1152 and shown exiting distal opening 1170 .
- Fluid such as, e.g., viscoelastic
- injected through this opening may be used, for example, to gently separate the walls of Schlemm's canal in areas where the canal walls have collapsed and or adhered to each other. The newly created space will provide a passageway for the cable to atraumatically advance without causing tearing or puncturing into the canal.
- liner tube 1158 is positioned so that its distal end extends through cable 1154 to a proximal surface of distal tip 1160 .
- liner tube 1158 ends proximally of the proximal surface of distal tip 1160 to expose a distal portion 1182 of cable 1154 to fluid (such as, e.g., viscoelastic) within lumen 1180 .
- fluid such as, e.g., viscoelastic
- Fluid injected between adjacent filars 1176 may be used, for example, to gently separate the walls of Schlemm's canal in areas where the canal walls have collapsed upon each other.
- FIG. 5 is a partial cross-sectional view showing a distal portion of a channel tool 2152 according to another embodiment of this invention.
- distal tip 2160 is closed, i.e., it lacks the distal opening shown in the embodiment of FIGS. 4A and 4B .
- Other elements of this embodiment are the same as those of the FIGS. 4A and 4B embodiment and therefore have the same element numbers.
- a distal portion 1182 of cable 1154 is exposed to fluid within lumen 1180 .
- fluid such as, e.g., viscoelastic
- Fluid injected between adjacent filars 1176 may be used, for example, to gently dilate the walls of Schlemm's canal to a larger dimension than the channel tool itself.
- An enlarged lumen is useful in accommodating an even larger device, such as an implant.
- the channel tools of this invention may be used to determine whether a portion of Schlemm's canal provides a suitable location for the delivery of an ocular implant.
- the channel tools may also be used to open a blocked or partially blocked portion of Schlemm's canal by injecting fluid (such as viscoelastic) and/or by mechanical force as the channel tool is advanced through Schlemm's canal.
- the channel tool may be used to deliver a canal dilation agent such as trypan blue or Indocyannine green (ICG), a colored agent or dye to provide enhanced viewing of the canal by a clinician and/or a therapeutic agent (such as, e.g., therapeutic agents enhancing the collector channels/trabecular meshwork, including ethacrynic acid, cytochalasin, rho kinase inhibitors).
- a therapeutic agent such as, e.g., therapeutic agents enhancing the collector channels/trabecular meshwork, including ethacrynic acid, cytochalasin, rho kinase inhibitors.
- enhanced viewing of Schlemm's canal may be achieved using a fluorescent dye in conjunction with black light.
- FIGS. 6-8 show details of a human eye.
- FIG. 6 is an enlarged perspective view illustrating a portion of eye 20 shown as a cross-sectional view created by a cutting plane passing through the center of pupil 32 .
- Eye 20 includes an iris 30 defining a pupil 32 .
- Eye 20 can be conceptualized as a fluid filled ball having two chambers.
- Sclera 34 of eye 20 surrounds a posterior chamber PC filled with a viscous fluid known as vitreous humor.
- Cornea 36 of eye 20 encloses an anterior chamber AC that is filled with a fluid know as aqueous humor.
- the cornea 36 meets the sclera 34 at a limbus 38 of eye 20 .
- a lens 40 of eye 20 is located between anterior chamber AC and posterior chamber PC. Lens 40 is held in place by a number of ciliary zonules 42 .
- the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor.
- a continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body.
- the ciliary body includes epithelial cells that continuously secrete aqueous humor.
- a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
- Schlemm's canal SC is a tube-like structure that encircles iris 30 . Two laterally cut ends of Schlemm's canal SC are visible in the cross-sectional view of FIG. 6 .
- aqueous humor flows out of anterior chamber AC and into Schlemm's canal SC.
- Aqueous humor exits Schlemm's canal SC and flows into a number of collector channels (shown as CC in FIG. 9 ).
- collector channels shown as CC in FIG. 9
- FIG. 7 is a stylized perspective view showing Schlemm's canal SC and iris 30 of eye 20 shown in the previous figure.
- Schlemm's canal SC is shown encircling iris 30 .
- Schlemm's canal SC may overhang iris 30 slightly.
- Iris 30 defines a pupil 32 .
- Schlemm's canal SC and iris 30 are shown in cross-section, with a cutting plane passing through the center of pupil 32 .
- Schlemm's canal SC is somewhat irregular, and can vary from patient to patient.
- the shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened. With reference to FIG. 7 , it will be appreciated that Schlemm's canal SC has a first major side 50 , a second major side 52 , a first minor side 54 , and a second minor side 56 .
- Schlemm's canal SC forms a ring around iris 30 with pupil 32 disposed in the center of that ring.
- First major side 50 is on the outside of the ring formed by Schlemm's canal SC and second major side 52 is on the inside of the ring formed by Schlemm's canal SC. Accordingly, first major side 50 may be referred to as an outer major side of Schlemm's canal SC and second major side 52 may be referred to as an inner major side of Schlemm's canal SC. With reference to FIG. 7 , it will be appreciated that first major side 50 is further from pupil 32 than second major side 52 .
- the high pressures inside the eye of a patient suffering from glaucoma may cause the inner major wall of Schlemm's canal to be pressed against the outer major wall of the canal.
- adhesions may form between the inner major wall and the outer major wall. These adhesions obstruct Schlemm's canal, inhibit circumferential flow and divide the canal into isolated compartments.
- Exemplary methods in accordance with this detailed description may be used by a physician to examine Schlemm's canal and identify to location and nature of such obstructions.
- a channel tool in accordance with this detailed description may be used to inject a fluid (e.g., dye) into Schlemm's canal.
- a fluid e.g., dye
- Schlemm's canal the physician may observe the movement of that fluid within Schlemm's canal using a microscope and a gonio lens as shown in FIG. 1 . Studying Schlemm's canal in this fashion allows the physician to achieve a clear understanding of the anatomical structure of the eye being studied. This knowledge will inform the physician's decision making when determining when and where to place aqueous humor drainage devices.
- FIG. 8 is an enlarged cross-sectional view further illustrating Schlemm's canal SC shown in the previous figure.
- Schlemm's canal SC has a wall W defining a lumen 58 .
- the shape of Schlemm's canal SC is somewhat irregular, and it can vary from patient to patient.
- the shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened.
- the cross-sectional shape of lumen 58 may be compared to the shape of an ellipse.
- a major axis 60 and a minor axis 62 of lumen 58 are illustrated with dashed lines in FIG. 8 .
- the length of major axis 60 and minor axis 62 can vary from patient to patient.
- the length of minor axis 62 is between one and thirty micrometers in most patients.
- the length of major axis 60 is between one hundred and fifty micrometers and three hundred and fifty micrometers in most patients.
- Schlemm's canal SC comprises a first major side 50 , a second major side 52 , a first minor side 54 , and a second minor side 56 .
- first major side 50 is longer than both first minor side 54 and second minor side 56 .
- second major side 52 is longer than both first minor side 54 and second minor side 56 .
- FIG. 9 is a stylized perspective view showing an eye 20 .
- the upper and lower eyelids of the eye are held open with surgical tools so that the eye is accessible to a physician.
- Cornea 24 of eye 20 meets the sclera 26 of eye 20 at the limbus.
- the Schlemm's canal SC of eye 20 is disposed below sclera 26 .
- Schlemm's canal SC is illustrated with dashed lines in FIG. 9 . These dashed lines generally encircle the iris 22 of eye 20 .
- Glaucoma may be treated, for example, by implanting one or more aqueous humor drainage devices in the eye.
- the several figures that follow illustrate exemplary methods of an ab externo approach for using a channel tool to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant and for placing an aqueous humor drainage device into an eye.
- Two incisions have been made in sclera 26 of eye 20 of FIG. 9 . These two incisions define a first scleral flap 28 .
- the two incisions defining first scleral flap 28 extend through less than the entire thickness of sclera 26 . Accordingly, these two incisions may be referred to as partial thickness incisions.
- first scleral flap 28 has been folded upward.
- FIG. 10 is an additional perspective view of eye 20 shown in the previous figure.
- Two additional incisions have been made in the eye 20 of FIG. 10 . These two additional incisions extend deeper into sclera 26 and define a second scleral flap 30 .
- the incisions made in sclera 26 have formed a recess 32 in eye 20 .
- second scleral flap 30 has been folded upward.
- second scleral flap 30 is surgically removed from eye 20 .
- the area formerly occupied by second scleral flap 30 may act as a reservoir for aqueous humor leaving anterior chamber AC. This reservoir may facilitate the flow of aqueous humor out of eye 20 .
- a portion of eye 20 is surrounded by a frame F in FIG. 10 . This portion of eye 20 will be enlarged for purposes of illustration in subsequent figures.
- FIG. 11 is an enlarged figure showing the portion of eye 20 surrounded by frame F.
- Incisions made in sclera 26 have formed a recess 32 in eye 20 .
- the incisions have cut through a wall 34 of Schlemm's canal SC and extend approximately halfway through Schlemm's canal SC.
- the wall 34 of Schlemm's canal SC defines a first opening 36 and a second opening 38 .
- Some exemplary methods in accordance with this detailed description may include the steps of advancing a first aqueous humor drainage device through first opening 36 and advancing a second aqueous humor drainage device through second opening 38 .
- a single aqueous humor drainage device may be inserted into Schlemm's canal.
- FIG. 12 is an additional enlarged figure showing the portion of eye 20 surrounded by frame F.
- Schlemm's canal SC is a somewhat placid channel encircling iris 22 .
- Iris 22 defines a pupil 44 .
- Schlemm's canal SC is a somewhat placid channel encircling iris 22 .
- Iris 22 defines a pupil 44 .
- Schlemm's canal of a patient suffering from glaucoma has lost some or all of its natural functionality. Due to the abnormal pressures caused by glaucoma, Schlemm's canal and related tissues may have lost the ability to respond (move) to pressure gradients. In some patients, these conditions may result in the collapse and subsequent closure of Schlemm's canal. When this is the case, the wall of Schlemm's canal may be pushed closed and may not be allowed to rebound to an open shape.
- a cannula 108 has been positioned proximate recess 32 .
- a distal tip portion 40 of cannula 108 has a blunt shape.
- distal tip portion 40 of cannula 108 is configured to be inserted partially or completely into an opening cut through the wall of Schlemm's canal.
- wall 34 of Schlemm's canal SC defines a first opening 36 and a second opening 38 .
- FIG. 13 is an additional perspective view showing a portion of eye 20 .
- distal tip portion 40 of cannula 108 has been positioned near an opening 38 cut through the wall 34 of Schlemm's canal SC.
- distal port 42 of cannula 108 is generally aligned with opening 38 defined by wall 34 of Schlemm's canal SC.
- Some methods in accordance with this detailed description may include the step of aligning the distal port of a cannula with an opening cut through the wall of Schlemm's canal.
- a channel tool may be advanced through the distal port of the cannula and through the opening defined by the wall of Schlemm's canal.
- the channel tool may be used, for example, to determine whether a portion of Schlemm's canal near the opening provides a suitable location for the delivery of an aqueous humor drainage device.
- the aqueous humor drainage device may be advanced through the distal port of the cannula and through the opening defined by the wall of Schlemm's canal.
- FIG. 14 is an additional perspective view showing a portion of eye 20 .
- a channel tool 154 and an aqueous humor drainage device 122 have been advanced into Schlemm's canal SC.
- channel tool 154 extends through distal port 42 of cannula 108 and through an opening 38 defined by wall 34 of Schlemm's canal SC.
- Channel tool 154 may be as described with respect to one of the embodiments described above.
- Therapy system 100 may include a mechanism that is capable of advancing and retracting the channel tool 154 .
- aqueous humor drainage device 122 is disposed about a distal portion of channel tool 154 .
- Aqueous humor drainage device 122 and channel tool 154 slidingly engage each other in the embodiment of FIG. 14 .
- Therapy system 100 may include a mechanism that is capable of advancing and retracting the aqueous humor drainage device 122 .
- the channel tool may be used to determine whether a Schlemm's canal portion provides a suitable location for the delivery of an ocular implant, such as aqueous humor drainage device 122 .
- Channel tool 154 is formed with sufficient column strength to enable the tool to be advanced through an open canal without kinking. A sensation of kinking or resistance as the channel tool is advanced into Schlemm's canal will provide a user of an indication that a portion of Schlemm's canal may be partially or completely blocked and therefore unsuitable for the delivery of an ocular implant.
- the channel tool 154 of therapy system 100 may have one or more distal openings that fluidly communicate with a fluid source for the injection of fluids (e.g., viscoelastic compositions) into Schlemm's canal during ophthalmic surgery.
- a fluid source for the injection of fluids (e.g., viscoelastic compositions) into Schlemm's canal during ophthalmic surgery.
- fluids e.g., viscoelastic compositions
- a viscoelastic gel-like composition can be used and introduced directly into the canal to protect sensitive tissues from trauma and to provide fluid pressure for expanding collapsed portions of the canal through controlled dilatation. Viscoelastic also provides a lubricious interface between the implant and the canal to facilitate placement.
- the injection of viscoelastic may aid in opening the canal and may provide a lubricious interface between the channel tool and the canal wall.
- FIG. 15 is an additional perspective view showing a portion of eye 20 .
- channel tool 154 has been retracted from Schlemm's canal SC leaving ocular implant 122 in place.
- therapy system 100 includes a mechanism that is capable of advancing and retracting of both channel tube 154 and a push tube (not shown). When this is the case, channel tool 154 may be retracted from Schlemm's canal while the push tube prevents aqueous humor drainage device 122 from being pulled proximally.
- FIG. 16 is an additional perspective view showing a portion of eye 20 .
- cannula tip 40 of cannula 108 has been moved away from Schlemm's canal SC.
- Aqueous humor drainage device 122 is shown residing in Schlemm's canal.
- the second scleral flap has been optionally surgically removed from eye 20 .
- the portion of recess 32 formerly occupied by second scleral flap 30 may act as a reservoir for aqueous humor leaving anterior chamber AC. This reservoir may facilitate the flow of aqueous humor out of anterior chamber AC.
- FIG. 17 is an additional perspective view showing a portion of eye 20 .
- first scleral flap 28 has been folded over recess 32 .
- first scleral flap 28 is secured to the remainder of sclera 26 with a plurality of sutures.
- FIG. 18A and FIG. 18B are stylized plan views showing an eye 20 .
- a recess 32 has been formed in eye 20 .
- a single aqueous humor drainage device 122 A has been advanced through a first opening 36 defined by the wall of Schlemm's canal of eye 20 .
- a first aqueous humor drainage device 122 A has been advanced through a first opening 36 defined by the wall of Schlemm's canal and a second aqueous humor drainage device 122 B has been advanced through a second opening 38 defined by the wall of Schlemm's canal.
- the implants shown in FIGS. 18A and 18B may be implanted according to the methods, and using the systems, described above.
- FIG. 19A and FIG. 19B are stylized plan views showing an eye 20 .
- a recess 32 has been formed in eye 20 .
- a first aqueous humor drainage device 122 has been advanced into Schlemm's canal of first eye 20 .
- an inlet portion 46 of first aqueous humor drainage device 122 has been positioned to extend into the anterior chamber AC of first eye 20 .
- the aqueous humor drainage device 122 in FIG. 19B lies entirely within Schlemm's canal and does not extend into the anterior chamber AC of eye 20 .
- Methods in accordance with this detailed description may include the step of advancing an inlet portion of a first aqueous humor drainage device into the anterior chamber of an eye.
- the implants shown in FIGS. 19A and 19B may be implanted according to the methods, and using the systems, described above.
- the methods illustrated in FIGS. 9-19 may be generally referred to as ab externo methods.
- Access to Schlemm's canal may be established using an ab interno approach or an ab externo approach.
- the ab externo methods described herein may be particularly useful when treating closed angle forms of glaucoma. Methods in accordance with this detailed description may include the steps of identifying a patient suffering from closed angle glaucoma and performing the method steps illustrated herein on the eye(s) of that patient.
- a substantially straight cannula (having, e.g., a blunt distal tip) is used in connection with ab externo approaches.
- FIGS. 2 and 20 - 22 show the use of an ab interno approach to deliver a channel tool and/or ocular implant according to embodiments of this invention.
- FIG. 20A shows a distal tip 202 of a delivery system cannula 200 passing through the anterior chamber AC of an eye.
- the inner major wall 252 of Schlemm's canal SC in apposition with the outer major wall 250 preventing circumferential flow within the canal and eliminating a flow path for aqueous access with the closest collector channel.
- the distal tip 202 of cannula 200 has passed through the trabecular meshwork TM so that at least a portion of a distal opening 204 of cannula 200 is within Schlemm's canal SC.
- a channel tool 226 is being advanced through distal opening 204 of cannula 200 into Schlemm's canal to determine whether that portion of Schlemm's canal provides a suitable location for the delivery of an ocular implant and/or to open that portion of Schlemm's canal, either through the mechanical action of the advancing channel tool, via the injection of a fluid such as viscoelastic, or both.
- FIG. 20C includes a plurality of arrows representing fluid flowing through the side walls of channel tool 226 . This fluid may be injected into Schlemm's canal in a series of controlled-volume increments to gently separate the walls of the canal in areas where Schlemm's canal is obstructed.
- FIG. 21 shows cannula 200 entering through the cornea of the eye into the anterior chamber and Schlemm's canal.
- FIGS. 22A-F show steps of a therapy method according to this invention.
- a cannula 200 has been inserted through the anterior chamber of the eye to place the distal tip 202 at least partially in Schlemm's canal SC.
- a channel tool 226 has been advanced out of cannula 200 into Schlemm's canal SC.
- a fluid 228 such as viscoelastic may be ejected from channel tool 226 into Schlemm's canal to provide lubrication for the advancement of channel tool 226 and/or to dilate Schlemm's canal.
- An ocular implant 250 may thereafter be placed in Schlemm's canal, as shown in FIG. 22F .
- a visible colorant may be added to the viscoelastic composition.
- the visible colorant may facilitate and evaluation of canal patency. The information gained during this may assist a physician in pre-screening a patient and predicting the potential success of an aqueous drainage aqueous humor drainage device placement procedure for that patient.
- FIG. 23A is a stylized perspective view illustrating an exemplary therapy system 3100 in accordance with this detailed description.
- FIG. 23B is an enlarged detail view further illustrating a portion of therapy system 3100 .
- FIG. 23A and FIG. 23B will be collectively referred to as FIG. 23 .
- the therapy system 3100 of FIG. 23 includes an ocular implant 3122 , a channel tool 3152 , a push tube 3190 , a cannula 3108 , and a fluid injection assembly 3162 .
- ocular implant 3122 may be used, for example, to determine whether Schlemm's canal of an eye provides a suitable location for the delivery of ocular implant 3122 , to open Schlemm's canal of the eye, and/or to place an ocular implant in Schlemm's canal of the eye.
- push tube 3190 and ocular implant 3122 are both disposed about channel tool 3152 .
- push tube 3190 can be seen extending through a distal port 3109 of cannula 3108 .
- a distal portion of channel tool 3152 can be seen extending beyond ocular implant 3122 in FIG. 23A .
- channel tool 3152 is slidingly disposed in lumens defined by push tube 3190 and ocular implant 3122 . Accordingly, channel tool 3152 is free to translate in axial directions (e.g., distal and proximal directions) with respect to both push tube 3190 and ocular implant 3122 .
- channel tool 3152 may be advanced beyond ocular implant 3122 and into Schlemm's canal.
- the distal end of channel tool 3152 may be advanced through a portion of Schlemm's canal, for example, to determine whether that portion of Schlemm's canal provides a suitable location for the delivery of ocular implant 3122 .
- the user may advance ocular implant 3122 into the identified portion of Schlemm's canal.
- ocular implant 3122 may be advanced using push tube 3190 .
- proximal control 3102 includes a first mechanism 3166 A and second mechanism 3166 B.
- First mechanism 3166 A is capable of advancing and retracting channel tool 3152 .
- Push tube 3190 may be advanced and retracted in axial directions by a second mechanism 3166 B.
- Cannula 3108 of therapy system 3100 is adapted and configured to deliver channel tool 3152 and ocular implant 3122 into Schlemm's canal of a human eye.
- a number of exemplary cannulas that may be used with the therapy systems described herein are disclosed in U.S. patent application Ser. No. 12/632,738. The disclosure of this U.S. patent application is hereby incorporated by reference in its entirety.
- Ocular implant 3122 of therapy system 3100 is adapted and configured to be disposed within Schlemm's canal of a human eye.
- Ocular implants that may be suitable in some applications are disclosed e.g., in U.S. Pat. No. 7,740,604; US Patent Publ. No. 2009/0082860; US Patent Publ. No. 2009/0227934; US Patent Publ. No. 2009/0132040; US Patent Publ. No. 2010/0121342; US Patent Publ. No. 2006/0195187; and U.S. application Ser. No. 12/833,863. The entire disclosure of these U.S. Patents and patent applications is hereby incorporated by reference.
- Fluid injection assembly 3162 may comprise, for example, a syringe (i.e., a piston disposed in a cylinder) that is filled with fluid. Fluid injection assembly 3162 may also include a mechanism configured to dispense a controlled volume of fluid each time an input element of the mechanism (e.g., a lever) is actuated. Fluid injection assembly 3162 fluidly communicates with channel tool 3152 via an injection tube 3156 .
- a syringe i.e., a piston disposed in a cylinder
- Fluid injection assembly 3162 may also include a mechanism configured to dispense a controlled volume of fluid each time an input element of the mechanism (e.g., a lever) is actuated. Fluid injection assembly 3162 fluidly communicates with channel tool 3152 via an injection tube 3156 .
- FIG. 24 is an enlarged plan view further illustrating ocular implant 3122 , push tube 3190 , and cannula 3108 .
- ocular implant 3122 and push tube 3190 are mechanically coupled to each other at a connection 3192 .
- an ear of ocular implant 3192 is received in an aperture defined by push tube 3190 .
- an ear of push tube 3190 is received in an aperture defined by ocular implant 3192 .
- Channel tool 3152 extends through connection 3192 in the embodiment of FIG. 24 .
- the presence of channel tool 3152 extending through ocular implant 3122 and push tube 3190 locks these two elements together.
- An area including connection 3192 is surrounded by a frame F in FIG. 24 . This area will be enlarged for purposes of illustration in subsequent figures.
- FIG. 25A and FIG. 25B are enlarged perspective views illustrating the connection formed between ocular implant 3122 and push tube 3190 .
- ocular implant 3122 and push tube 3190 are mechanically coupled at a connection 3192 .
- the connection between ocular implant 3122 and push tube 3190 has been broken.
Abstract
An ocular implant and delivery system having a channel tool adapted to extend through at least a portion of Schlemm's canal of a human eye and to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant; an ocular implant adapted to be disposed within Schlemm's canal of a human eye; and a cannula comprising a distal opening adapted to deliver the channel tool and the ocular implant into Schlemm's canal of the eye. The invention also provides a method of treating glaucoma in a human eye including the steps of inserting a distal exit port of a cannula at least partially into Schlemm's canal of the eye; delivering a channel tool through the cannula into Schlemm's canal; delivering an ocular implant through the cannula into Schlemm's canal; and removing the channel tool and the cannula from the eye while leaving the ocular implant in place within Schlemm's canal.
Description
- This application claims the benefit under 35 U.S.C. §119 of U.S. Provisional Application No. 61/254,523 filed Oct. 23, 2009, the disclosure of which is incorporated herein by reference.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- According to a draft report by The National Eye Institute (NEI) at The United States National Institutes of Health (NIH), glaucoma is now the leading cause of irreversible blindness worldwide and the second leading cause of blindness, behind cataract, in the world. Thus, the NEI draft report concludes, “it is critical that significant emphasis and resources continue to be devoted to determining the pathophysiology and management of this disease.” Glaucoma researchers have found a strong correlation between high intraocular pressure and glaucoma.
- In addition to drug treatments, a variety of surgical treatments for glaucoma have been described. For example, shunts were implanted to direct aqueous humor from the anterior chamber to the extraocular vein (Lee and Scheppens, “Aqueous-venous shunt and intraocular pressure,” Investigative Ophthalmology (February 1966)). Other early glaucoma treatment implants led from the anterior chamber to a sub-conjunctival bleb (e.g., U.S. Pat. No. 4,968,296 and U.S. Pat. No. 5,180,362). Still others were shunts leading from the anterior chamber to a point just inside Schlemm's canal (Spiegel et al., “Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG?” Ophthalmic Surgery and Lasers (June 1999); U.S. Pat. No. 6,450,984; U.S. Pat. No. 6,450,984).
- More recently, glaucoma treatment devices that are disposed partially or completely within Schlemm's canal have been described. Examples of such devices may be found, e.g., in U.S. Pat. No. 7,740,604; US Patent Publ. No. 2009/0082860; US Patent Publ. No. 2009/0227934; US Patent Publ. No. 2009/0132040; US Patent Publ. No. 2010/0121342; US Patent Publ. No. 2006/0195187; and U.S. application Ser. No. 12/833,863.
- In some cases, the Schlemm's canal of a patient suffering from glaucoma has lost some or all of its natural functionality. Due to the abnormal pressures caused by glaucoma, Schlemm's canal and related tissues may have lost the ability to move. In some patients, these conditions may result in the collapse and subsequent closure of part or all of Schlemm's canal. When this is the case, portions of the wall of Schlemm's canal may be pushed closed and may not be allowed to rebound to an open shape. Over time, the collapsed wall of Schlemm's canal may adhere to itself causing the canal to become compartmentalized. Prior to implantation of an implant into Schlemm's canal, therefore, it may be advantageous to determine whether the lumen of Schlemm's canal is partially or completely blocked, i.e., to establish and confirm that enough space exists for an implant to reside and optionally to open up part of all of the canal lumen.
- One aspect of the invention provides an ocular implant and delivery system having a channel tool (such as a torque tube or coil) adapted to extend through at least a portion of Schlemm's canal of a human eye and to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant; an ocular implant adapted to be disposed within Schlemm's canal of a human eye; and a cannula comprising a distal opening adapted to deliver the channel tool and the ocular implant into Schlemm's canal of the eye. In some embodiments, the channel tool is further adapted to open a channel within the Schlemm's canal portion.
- Some embodiments of the invention also have a proximal control adapted to be operated from exterior to the eye to move the channel opening tool and the ocular implant when the distal opening of the cannula is within the eye. The channel opening tool may be configured to be disposed within the ocular implant and to move with respect to the ocular implant.
- In some embodiments, the system includes a fluid and a fluid injection mechanism adapted to inject the fluid (such as, e.g., a dilatation agent adapted to dilate tissue) into Schlemm's canal of the eye through the cannula. In some such embodiments, the channel opening tool has a fluid lumen and the fluid injection mechanism is adapted to inject fluid through the channel opening tool fluid lumen. In some such embodiments, the channel opening tool may have a distal opening communicating with the fluid lumen and/or a liner tube surrounding the fluid lumen.
- In some embodiments, the fluid injection mechanism has a piston disposed in a cylinder. In such embodiments in which the proximal control includes a handle, the fluid injection mechanism may also include an injection tube extending from an outlet of the cylinder to the handle.
- Another aspect of the invention provides a method of treating glaucoma in a human eye including the steps of: inserting a distal exit port of a cannula at least partially into Schlemm's canal of the eye; delivering a channel tool through the cannula into Schlemm's canal; delivering an ocular implant through the cannula into Schlemm's canal; and removing the channel tool and the cannula from the eye while leaving the ocular implant in place within Schlemm's canal. In some embodiments, the method includes the step of delivering a dye through the channel tool and observing the behavior of the dye to identify the location of obstructions within Schlemm's canal.
- In some embodiments, the method includes the step of opening a channel in Schlemm's canal with the channel tool. The step of opening a channel may include the step of moving the channel tool within Schlemm's canal. The step of opening a channel may include the step of delivering a fluid (such as a dilatation agent, a therapeutic agent and/or a dye) through the channel tool by, e.g., moving the fluid through an obstruction within Schlemm's canal to increase fluid communication between adjacent segments of Schlemm's canal.
- In some embodiments, the delivering steps include the step of delivering the channel opening tool and the ocular implant without removing the distal tip of the cannula from the eye. Some embodiments of the method include the step of moving the channel opening tool and the ocular implant with respect to each other within Schlemm's canal.
- In some embodiments, the delivering steps include the step of delivering the ocular implant over the channel opening tool. In some embodiments, the inserting step includes the step of inserting the distal exit port of the cannula at least partially into Schlemm's canal of the eye through an ab interno approach. In other embodiments, the inserting step includes the step of inserting the distal exit port of the cannula at least partially into Schlemm's canal of the eye through an ab externo approach.
- Yet another aspect of the invention provides an ocular implant and delivery system including a channel tool adapted to extend through at least a portion of Schlemm's canal of a human eye and to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant; a cannula comprising a distal opening adapted to deliver the channel tool and the ocular implant into Schlemm's canal of the eye; and a proximal control adapted to move the channel tool with respect to the cannula.
- Still another aspect of the invention provides a method of treating glaucoma in a human eye including the steps of inserting a distal exit port of a cannula at least partially into Schlemm's canal of the eye; delivering a channel tool through the cannula into Schlemm's canal using a proximal control; and removing the channel tool and the cannula from the eye while leaving the ocular implant in place within Schlemm's canal.
- The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 is a stylized representation of an exemplary medical procedure in accordance with this detailed description. -
FIGS. 2A and 2C are perspective views illustrating an ocular implant and delivery system and method according to an embodiment of this invention. -
FIG. 2B is an enlarged perspective view of a cannula and channel tool of the system shown inFIG. 2A . -
FIG. 3 is a stylized partial cross-sectional and partial plan view of an ocular implant and delivery system according to an embodiment of this invention. -
FIG. 4A is a partial cross-sectional view of a distal portion of a channel tool according to an embodiment of this invention. -
FIG. 4B is a partial cross-sectional view of a distal portion of a channel tool according to another embodiment of this invention. -
FIG. 5 is a partial cross-sectional view of a distal portion of a channel tool according to yet another embodiment of this invention. -
FIG. 6 is a stylized perspective view illustrating the anatomy of an eye. -
FIG. 7 is a stylized perspective view showing Schlemm's canal and an iris of the eye shown in the previous figure. -
FIG. 8 is an enlarged cross-sectional view further illustrating Schlemm's canal shown in the previous figure. -
FIG. 9 is a stylized perspective view of an eye in which a scleral flap has been formed. -
FIG. 10 is a stylized perspective view of the eye ofFIG. 9 in which a second scleral flap has been formed. -
FIG. 11 is a stylized perspective view of the eye ofFIGS. 9 and 10 in which openings have been made in Schlemm's canal. -
FIG. 12 is a stylized perspective view of the eye ofFIGS. 9-11 showing a cannula proximate the eye. -
FIG. 13 is a stylized perspective view of the eye ofFIGS. 9-12 showing the insertion of a distal tip of a cannula into Schlemm's canal. -
FIG. 14 is a stylized perspective view of the eye ofFIGS. 9-13 showing a channel tool and ocular implant being advanced out of the cannula and into Schlemm's canal. -
FIG. 15 is a stylized perspective view of the eye ofFIGS. 9-14 showing retraction of the channel tool from Schlemm's canal, leaving the ocular implant in Schlemm's canal. -
FIG. 16 is a stylized perspective view of the eye ofFIGS. 9-15 showing removal of the cannula from the eye. -
FIG. 17 is a stylized perspective view of the eye ofFIGS. 9-16 showing closing of the scleral flap. -
FIGS. 18A and 18B are stylized perspective views of eyes in which ocular implants have been placed in Schlemm's canal. -
FIG. 19A is a stylized perspective view of an eye in which an ocular implant has been placed with an inlet in the anterior chamber and the remainder of the device in Schlemm's canal. -
FIG. 19B is a stylized perspective view of an eye in which an ocular implant has been placed so that it lies entirely within Schlemm's canal. -
FIGS. 20A-D and 21 show details of a method of using the system of this invention. -
FIGS. 22A-F show details of a method of using the system of this invention. -
FIG. 23A is a perspective view of certain components of an ocular implant and delivery system according to an embodiment of this invention. -
FIG. 23B is a detail view of the distal end of the system shown inFIG. 23A . -
FIG. 24 is an elevational view of a cannula, push tube ocular plant of a system according to an embodiment of this invention. -
FIGS. 25A-B show details of the connection between the ocular implant and push tube shown inFIG. 24 . - The following detailed description should be read with reference to the drawings, in which like elements in different drawings are numbered identically. The drawings, which are not necessarily to scale, depict exemplary embodiments and are not intended to limit the scope of the invention. Examples of constructions, materials, dimensions, and manufacturing processes are provided for selected elements. All other elements employ that which is known to those of skill in the field of the invention. Those skilled in the art will recognize that many of the examples provided have suitable alternatives that can be utilized.
-
FIG. 1 is a stylized representation of an exemplary medical procedure in accordance with this detailed description. In this exemplary medical procedure, a physician is treating aneye 20 of a patient P using atherapy system 100, such as an ocular implant and delivery system. In the exemplary procedure ofFIG. 1 , the physician is holding a handle portion oftherapy system 100 in his or her right hand RH. The physician's left hand (not shown) may be used to hold the handle H of agonio lens 23. It will be appreciated that some physician's may prefer holding the therapy system handle in the left hand and the gonio lens handle H in the right hand RH. - During the exemplary procedure illustrated in
FIG. 1 , the physician may view the interior of the anterior chamber usinggonio lens 23 and amicroscope 25. Detail A ofFIG. 1 is a stylized simulation of the image viewed by the physician. A distal portion of acannula 102 is visible in Detail A. A shadow-like line indicates the location of Schlemm's canal SC which is lying under various tissue (e.g., the trabecular meshwork) that surround the anterior chamber. Adistal opening 104 ofcannula 102 is positioned near Schlemm's canal SC ofeye 20. In some methods in accordance with this detailed description,distal opening 104 ofcannula 102 is placed in fluid communication with Schlemm's canal SC. When this is the case, a device (e.g., an implant or a delivery tool for an implant) may be advanced throughdistal opening 104 and into Schlemm's canal SC. -
FIG. 2A is a perspective view further illustratingtherapy system 100 andeye 20 shown in the previous figure. InFIG. 2A ,cannula 102 oftherapy system 100 is shown extending through acornea 40 ofeye 20. A distal portion ofcannula 102 is disposed inside the anterior chamber defined bycornea 40 ofeye 20. In the embodiment ofFIG. 2A ,cannula 102 is configured so that adistal opening 104 ofcannula 102 can be placed in fluid communication with Schlemm's canal. - In the embodiment of
FIGS. 2A and 2B , achannel tool 126 is disposed in a lumen defined bycannula 102.Therapy system 100 includes a mechanism that is capable of advancing and retracting the channel tool along the length ofcannula 102. Thechannel tool 126 may be placed in Schlemm's canal ofeye 20 by advancing the channel tool throughdistal opening 104 ofcannula 102 whiledistal opening 104 is in fluid communication with Schlemm's canal. -
FIG. 2B is an enlarged detail view further illustratingcannula 102 oftherapy system 100. In the illustrative embodiment ofFIG. 2B ,channel tool 126 has been advanced throughdistal opening 104 ofcannula 102.Cannula 102 ofFIG. 2B defines apassageway 124 that fluidly communicates withdistal opening 104.Channel tool 126 may be moved alongpassageway 124 and throughdistal opening 104 bytherapy system 100.Therapy system 100 includes aproximal control mechanism 101 disposed outside of the eye that is capable of performing this function. -
FIG. 2C is an enlarged perspective view further illustratingeye 20 shown inFIG. 2A . InFIG. 2C , acannula 102 of atherapy system 100 can be seen extending throughcornea 40 ofeye 20 so that a distal portion D ofcannula 102 disposed in the anterior chamber AC ofeye 20. A proximal portion P ofcannula 102 disposed outside anterior chamber AC inFIG. 2C . In the embodiment ofFIG. 2C ,cannula 102 has been positioned so thatdistal port 104 ofcannula 102 is in fluid communication with Schlemm's canal ofeye 20. Achannel tool 126 oftherapy system 100 has been advance throughdistal port 104 ofcannula 102 and into Schlemm's canal ofeye 20. -
FIG. 3 is a stylized plan view illustrating anexemplary therapy system 1100 in accordance with this detailed description. Thetherapy system 1100 ofFIG. 3 includes achannel tool 1152, acannula 1108, and afluid injection assembly 1162. In the embodiment ofFIG. 3 ,fluid injection assembly 1162 includes a syringe (i.e., a piston disposed in a cylinder) 1163 that is filled with fluid 1164.Therapy system 1100 ofFIG. 3 may be used, for example, to determine whether Schlemm's canal of an eye provides a suitable location for the delivery of an ocular implant and/or to open Schlemm's canal of the eye. - Exemplary methods in accordance with this detailed description may include the step of advancing a distal portion of
channel tool 1152 through thedistal port 1109 ofcannula 1108 into Schlemm's canal of an eye. If resistance is encountered aschannel tool 1152 is advanced, the user is provided with an indication that Schlemm's canal is partially or completely blocked. Thechannel tool 1152 may be advanced through the blockage to open a channel in Schlemm's canal and/or to increase fluid communication between adjacent segments of Schlemm's canal. Alternatively or additionally, the channel tool may also used to inject fluid 1164 into Schlemm's canal to open the canal and/or to provide lubrication for further advancement of the channel tool into the canal. In addition to locating obstructions using tactile feel, a physician may usechannel tool 1152 to visually identify obstructions. For example,channel tool 1152 may be used to inject a visualization enhancing fluid (e.g., a dye) into Schlemm's canal. As fluid is injected into Schlemm's canal, the physician may observe the movement of that fluid within Schlemm's canal using a microscope and a gonio lens as shown inFIG. 1 .Therapy system 1100 may also be used to deliver an implant, such as an aqueous humor drainage device, into Schlemm's canal of the eye. When this is the case, the aqueous humor drainage device may be mounted onchannel tool 1152. - In
FIG. 3 ,channel tool 1152 is shown extending through adistal port 1109 ofcannula 1108.Cannula 1108 is coupled to aproximal control 1102 oftherapy system 1100.Proximal control 1102 includes amechanism 1166 that is capable of advancing and retractingchannel tool 1152. In the exemplary embodiment ofFIG. 3 ,mechanism 1166 is substantially disposed insideproximal control 1102. - In the embodiment of
FIG. 3 ,channel tool 1152 includes a coiled cable. Aninjection tube 1156 extends from afluid injection port 1168 insyringe 1163 throughproximal control 1102 to deliver fluid 1164 tochannel tool 1152.Fluid 1164 that has exitedchannel tool 1152 is represented by a number of fluid drops in the stylized plan view ofFIG. 3 .Fluid injection assembly 1162 includes a mechanism including a lever. The mechanism cooperates withsyringe 1163 to dispense fluid (e.g., the drops shown inFIG. 3 ). In the exemplary embodiment ofFIG. 3 ,fluid injection assembly 1162 will dispense a controlled volume of fluid each time the lever is actuated. In some exemplary methods, fluid is injected into Schlemm's canal as a series of controlled-volume increments to gently separate the walls of the canal in areas where Schlemm's canal is obstructed. It will be appreciated that other embodiments of thefluid injection assembly 1162 are possible without deviating from the spirit and scope of the present detailed description. For example,fluid injection assembly 1162 may employ a screw type ratcheting plunger which can dispense a controlled volume per click of the ratchet mechanism. - It will be appreciated that fluid 1164 may comprise various materials without deviating from the spirit and scope of the present detailed description. Examples of fluids that may be suitable in some applications include water, saline, hyaluronic acid and/or viscoelastic. The term “viscoelastic” is sometimes used to describe various viscoelastic materials that are injected into the eye as part of a surgical procedure. Viscoelastics for use in ophthalmic surgery are commercially available from Bausch and Lomb Incorporated (Rochester, N.Y., U.S.A.) and Alcon, Incorporated (Hünenberg, Switzerland). Viscoelastics may comprise, for example, hyaluronic acid. Hyaluronic acid is a material that is naturally found in the vitreous humor that fills the posterior chamber of the eye. Accordingly, this material is well suited for use in ophthalmic surgery. Hyaluronic acid is also known as hyaluronan and hyaluronate.
- With reference to
FIG. 3 , aloop 1172 is formed ininjection tube 1156. In some useful embodiments,loop 1172 is sized to provide a level of travel necessary to advance the distalend channel tool 1152 through the entire length of Schlemm's canal. In the exemplary embodiment ofFIG. 3 ,loop 1172 is disposed insideproximal control 1102. -
FIG. 4A is a partial cross-sectional view showing a distal portion of anexemplary channel tool 1152 in accordance with this detailed description. In this embodiment,channel tool 1152 includes acable 1154 and adistal tip 1160 at the distal end ofcable 1154.Distal tip 1160 may be attached tocable 1154, for example, by welding.Distal tip 1160 is rounded so as to be atraumatic.Distal tip 1160 has atip lumen 1174 fluidly communicating with adistal opening 1170. In this embodiment,cable 1154 is formed as a helical coil (formed, e.g., from stainless steel, nitinol or other suitable material) having a plurality offilars 1176 forming a hollow tube-like structure. In some particularly useful embodiments,cable 1154 comprises a torque cable. Torque cables that may be suitable in some applications are commercially available from Fort Wayne Metals, Inc. (Fort Wayne, Ind., U.S.A) and Asahi Intecc Co. Ltd. (Nagoya, Aichi Prefecture, Japan). In the embodiment ofFIG. 4A , each filar 1176 has a generally helical shape. In the embodiment ofFIG. 4A , filars 1176 ofcable 1154 define acable lumen 1178. Lubricity of the coil can be enhanced by the application of a surface coating (PTFE, heparin, etc.) which will further reduce potential trauma and facilitate smooth predictable advancement. Aliner tube 1158 is disposed insidecable lumen 1178.Liner tube 1158 may be formed, e.g., from polyimide and defines aliner lumen 1180 that fluidly communicates withtip lumen 1174 defined bydistal tip 1160.FIG. 4A includes a plurality of arrows representing fluid 1164 flowing throughtip lumen 1174 ofchannel tool 1152 and shown exitingdistal opening 1170. Fluid (such as, e.g., viscoelastic) injected through this opening may be used, for example, to gently separate the walls of Schlemm's canal in areas where the canal walls have collapsed and or adhered to each other. The newly created space will provide a passageway for the cable to atraumatically advance without causing tearing or puncturing into the canal. - In the view of
FIG. 4A ,liner tube 1158 is positioned so that its distal end extends throughcable 1154 to a proximal surface ofdistal tip 1160. In the view ofFIG. 4B ,liner tube 1158 ends proximally of the proximal surface ofdistal tip 1160 to expose adistal portion 1182 ofcable 1154 to fluid (such as, e.g., viscoelastic) withinlumen 1180. This fluid can then flow betweenadjacent filars 1176 ofcable 1154, as shown byarrows 1164. Fluid injected betweenadjacent filars 1176 may be used, for example, to gently separate the walls of Schlemm's canal in areas where the canal walls have collapsed upon each other. -
FIG. 5 is a partial cross-sectional view showing a distal portion of achannel tool 2152 according to another embodiment of this invention. In this embodiment,distal tip 2160 is closed, i.e., it lacks the distal opening shown in the embodiment ofFIGS. 4A and 4B . Other elements of this embodiment are the same as those of theFIGS. 4A and 4B embodiment and therefore have the same element numbers. As shown inFIG. 5 , adistal portion 1182 ofcable 1154 is exposed to fluid withinlumen 1180. When this is the case, fluid (such as, e.g., viscoelastic) can flow betweenadjacent filars 1176 ofcable 1154. Fluid injected betweenadjacent filars 1176 may be used, for example, to gently dilate the walls of Schlemm's canal to a larger dimension than the channel tool itself. An enlarged lumen is useful in accommodating an even larger device, such as an implant. - The channel tools of this invention (such as
channel tools - The system of this invention may be used to deploy a channel tool and/or an ocular implant via an ab interno approach or an ab externo approach.
FIGS. 6-8 show details of a human eye.FIG. 6 is an enlarged perspective view illustrating a portion ofeye 20 shown as a cross-sectional view created by a cutting plane passing through the center ofpupil 32.Eye 20 includes aniris 30 defining apupil 32.Eye 20 can be conceptualized as a fluid filled ball having two chambers.Sclera 34 ofeye 20 surrounds a posterior chamber PC filled with a viscous fluid known as vitreous humor.Cornea 36 ofeye 20 encloses an anterior chamber AC that is filled with a fluid know as aqueous humor. Thecornea 36 meets the sclera 34 at alimbus 38 ofeye 20. Alens 40 ofeye 20 is located between anterior chamber AC and posterior chamber PC.Lens 40 is held in place by a number ofciliary zonules 42. - Whenever a person views an object, he or she is viewing that object through the cornea, the aqueous humor, and the lens of the eye. In order to be transparent, the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
- Schlemm's canal SC is a tube-like structure that encircles
iris 30. Two laterally cut ends of Schlemm's canal SC are visible in the cross-sectional view ofFIG. 6 . In a healthy eye, aqueous humor flows out of anterior chamber AC and into Schlemm's canal SC. Aqueous humor exits Schlemm's canal SC and flows into a number of collector channels (shown as CC inFIG. 9 ). After leaving Schlemm's canal SC, aqueous humor is absorbed into the venous blood stream and carried out of the eye. -
FIG. 7 is a stylized perspective view showing Schlemm's canal SC andiris 30 ofeye 20 shown in the previous figure. InFIG. 7 , Schlemm's canal SC is shown encirclingiris 30. With reference toFIG. 7 , it will be appreciated that Schlemm's canal SC mayoverhang iris 30 slightly.Iris 30 defines apupil 32. In the exemplary embodiment ofFIG. 7 , Schlemm's canal SC andiris 30 are shown in cross-section, with a cutting plane passing through the center ofpupil 32. - The shape of Schlemm's canal SC is somewhat irregular, and can vary from patient to patient. The shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened. With reference to
FIG. 7 , it will be appreciated that Schlemm's canal SC has a firstmajor side 50, a secondmajor side 52, a firstminor side 54, and a secondminor side 56. - Schlemm's canal SC forms a ring around
iris 30 withpupil 32 disposed in the center of that ring. Firstmajor side 50 is on the outside of the ring formed by Schlemm's canal SC and secondmajor side 52 is on the inside of the ring formed by Schlemm's canal SC. Accordingly, firstmajor side 50 may be referred to as an outer major side of Schlemm's canal SC and secondmajor side 52 may be referred to as an inner major side of Schlemm's canal SC. With reference toFIG. 7 , it will be appreciated that firstmajor side 50 is further frompupil 32 than secondmajor side 52. The high pressures inside the eye of a patient suffering from glaucoma, may cause the inner major wall of Schlemm's canal to be pressed against the outer major wall of the canal. Over time, adhesions may form between the inner major wall and the outer major wall. These adhesions obstruct Schlemm's canal, inhibit circumferential flow and divide the canal into isolated compartments. Exemplary methods in accordance with this detailed description may be used by a physician to examine Schlemm's canal and identify to location and nature of such obstructions. For example, a channel tool in accordance with this detailed description may be used to inject a fluid (e.g., dye) into Schlemm's canal. As fluid is injected into Schlemm's canal, the physician may observe the movement of that fluid within Schlemm's canal using a microscope and a gonio lens as shown inFIG. 1 . Studying Schlemm's canal in this fashion allows the physician to achieve a clear understanding of the anatomical structure of the eye being studied. This knowledge will inform the physician's decision making when determining when and where to place aqueous humor drainage devices. -
FIG. 8 is an enlarged cross-sectional view further illustrating Schlemm's canal SC shown in the previous figure. As shown inFIG. 8 , Schlemm's canal SC has a wall W defining alumen 58. The shape of Schlemm's canal SC is somewhat irregular, and it can vary from patient to patient. The shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened. The cross-sectional shape oflumen 58 may be compared to the shape of an ellipse. Amajor axis 60 and aminor axis 62 oflumen 58 are illustrated with dashed lines inFIG. 8 . - The length of
major axis 60 andminor axis 62 can vary from patient to patient. The length ofminor axis 62 is between one and thirty micrometers in most patients. The length ofmajor axis 60 is between one hundred and fifty micrometers and three hundred and fifty micrometers in most patients. - With reference to
FIG. 8 , it will be appreciated that Schlemm's canal SC comprises a firstmajor side 50, a secondmajor side 52, a firstminor side 54, and a secondminor side 56. In the exemplary embodiment ofFIG. 8 , firstmajor side 50 is longer than both firstminor side 54 and secondminor side 56. Also in the exemplary embodiment ofFIG. 8 , secondmajor side 52 is longer than both firstminor side 54 and secondminor side 56. -
FIG. 9 is a stylized perspective view showing aneye 20. In the embodiment ofFIG. 9 , the upper and lower eyelids of the eye are held open with surgical tools so that the eye is accessible to a physician.Cornea 24 ofeye 20 meets thesclera 26 ofeye 20 at the limbus. The Schlemm's canal SC ofeye 20 is disposed belowsclera 26. Schlemm's canal SC is illustrated with dashed lines inFIG. 9 . These dashed lines generally encircle theiris 22 ofeye 20. - Glaucoma may be treated, for example, by implanting one or more aqueous humor drainage devices in the eye. The several figures that follow illustrate exemplary methods of an ab externo approach for using a channel tool to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant and for placing an aqueous humor drainage device into an eye. Two incisions have been made in
sclera 26 ofeye 20 ofFIG. 9 . These two incisions define a firstscleral flap 28. The two incisions defining firstscleral flap 28 extend through less than the entire thickness ofsclera 26. Accordingly, these two incisions may be referred to as partial thickness incisions. As shown inFIG. 9 , firstscleral flap 28 has been folded upward. -
FIG. 10 is an additional perspective view ofeye 20 shown in the previous figure. Two additional incisions have been made in theeye 20 ofFIG. 10 . These two additional incisions extend deeper intosclera 26 and define a secondscleral flap 30. The incisions made insclera 26 have formed arecess 32 ineye 20. InFIG. 10 , secondscleral flap 30 has been folded upward. In some useful embodiments, secondscleral flap 30 is surgically removed fromeye 20. When this is the case, the area formerly occupied by secondscleral flap 30 may act as a reservoir for aqueous humor leaving anterior chamber AC. This reservoir may facilitate the flow of aqueous humor out ofeye 20. For purposes of illustration, a portion ofeye 20 is surrounded by a frame F inFIG. 10 . This portion ofeye 20 will be enlarged for purposes of illustration in subsequent figures. -
FIG. 11 is an enlarged figure showing the portion ofeye 20 surrounded by frame F. Incisions made insclera 26 have formed arecess 32 ineye 20. The incisions have cut through awall 34 of Schlemm's canal SC and extend approximately halfway through Schlemm's canal SC. Thewall 34 of Schlemm's canal SC defines afirst opening 36 and asecond opening 38. Some exemplary methods in accordance with this detailed description may include the steps of advancing a first aqueous humor drainage device throughfirst opening 36 and advancing a second aqueous humor drainage device throughsecond opening 38. In some cases, a single aqueous humor drainage device may be inserted into Schlemm's canal. -
FIG. 12 is an additional enlarged figure showing the portion ofeye 20 surrounded by frame F. Schlemm's canal SC is a somewhat placidchannel encircling iris 22.Iris 22 defines apupil 44. In some cases, the Schlemm's canal of a patient suffering from glaucoma has lost some or all of its natural functionality. Due to the abnormal pressures caused by glaucoma, Schlemm's canal and related tissues may have lost the ability to respond (move) to pressure gradients. In some patients, these conditions may result in the collapse and subsequent closure of Schlemm's canal. When this is the case, the wall of Schlemm's canal may be pushed closed and may not be allowed to rebound to an open shape. Over time, the collapsed wall of Schlemm's canal may adhere to itself causing the canal to become compartmentalized. Acannula 108 has been positionedproximate recess 32. In the embodiment ofFIG. 12 , adistal tip portion 40 ofcannula 108 has a blunt shape. Embodiments are also possible in whichdistal tip portion 40 ofcannula 108 is configured to be inserted partially or completely into an opening cut through the wall of Schlemm's canal. In the embodiment ofFIG. 12 ,wall 34 of Schlemm's canal SC defines afirst opening 36 and asecond opening 38. -
FIG. 13 is an additional perspective view showing a portion ofeye 20. In the embodiment ofFIG. 13 ,distal tip portion 40 ofcannula 108 has been positioned near anopening 38 cut through thewall 34 of Schlemm's canal SC. With reference toFIG. 13 , it will be appreciated thatdistal port 42 ofcannula 108 is generally aligned with opening 38 defined bywall 34 of Schlemm's canal SC. Some methods in accordance with this detailed description may include the step of aligning the distal port of a cannula with an opening cut through the wall of Schlemm's canal. A channel tool may be advanced through the distal port of the cannula and through the opening defined by the wall of Schlemm's canal. The channel tool may be used, for example, to determine whether a portion of Schlemm's canal near the opening provides a suitable location for the delivery of an aqueous humor drainage device. In some cases, the aqueous humor drainage device may be advanced through the distal port of the cannula and through the opening defined by the wall of Schlemm's canal. -
FIG. 14 is an additional perspective view showing a portion ofeye 20. In the embodiment ofFIG. 14 , achannel tool 154 and an aqueoushumor drainage device 122 have been advanced into Schlemm's canal SC. As shown inFIG. 14 ,channel tool 154 extends throughdistal port 42 ofcannula 108 and through anopening 38 defined bywall 34 of Schlemm's canal SC.Channel tool 154 may be as described with respect to one of the embodiments described above.Therapy system 100 may include a mechanism that is capable of advancing and retracting thechannel tool 154. In this embodiment, aqueoushumor drainage device 122 is disposed about a distal portion ofchannel tool 154. Aqueoushumor drainage device 122 andchannel tool 154 slidingly engage each other in the embodiment ofFIG. 14 .Therapy system 100 may include a mechanism that is capable of advancing and retracting the aqueoushumor drainage device 122. - The channel tool may be used to determine whether a Schlemm's canal portion provides a suitable location for the delivery of an ocular implant, such as aqueous
humor drainage device 122.Channel tool 154 is formed with sufficient column strength to enable the tool to be advanced through an open canal without kinking. A sensation of kinking or resistance as the channel tool is advanced into Schlemm's canal will provide a user of an indication that a portion of Schlemm's canal may be partially or completely blocked and therefore unsuitable for the delivery of an ocular implant. - As described above, in some useful embodiments the
channel tool 154 oftherapy system 100 may have one or more distal openings that fluidly communicate with a fluid source for the injection of fluids (e.g., viscoelastic compositions) into Schlemm's canal during ophthalmic surgery. In ophthalmic surgical procedures requiring the placement of an aqueous humor drainage device in Schlemm's canal, a viscoelastic gel-like composition can be used and introduced directly into the canal to protect sensitive tissues from trauma and to provide fluid pressure for expanding collapsed portions of the canal through controlled dilatation. Viscoelastic also provides a lubricious interface between the implant and the canal to facilitate placement. When a channel tool is moved into Schlemm's canal to establish fluid flow between pockets or compartments along the canal (with or without an aqueous humor drainage device disposed about the torque cable), the injection of viscoelastic may aid in opening the canal and may provide a lubricious interface between the channel tool and the canal wall. -
FIG. 15 is an additional perspective view showing a portion ofeye 20. In the embodiment ofFIG. 15 ,channel tool 154 has been retracted from Schlemm's canal SC leavingocular implant 122 in place. In some useful embodiments,therapy system 100 includes a mechanism that is capable of advancing and retracting of bothchannel tube 154 and a push tube (not shown). When this is the case,channel tool 154 may be retracted from Schlemm's canal while the push tube prevents aqueoushumor drainage device 122 from being pulled proximally. -
FIG. 16 is an additional perspective view showing a portion ofeye 20. In the embodiment ofFIG. 16 ,cannula tip 40 ofcannula 108 has been moved away from Schlemm's canal SC. Aqueoushumor drainage device 122 is shown residing in Schlemm's canal. As shown, the second scleral flap has been optionally surgically removed fromeye 20. The portion ofrecess 32 formerly occupied by secondscleral flap 30 may act as a reservoir for aqueous humor leaving anterior chamber AC. This reservoir may facilitate the flow of aqueous humor out of anterior chamber AC. -
FIG. 17 is an additional perspective view showing a portion ofeye 20. In the embodiment ofFIG. 17 , firstscleral flap 28 has been folded overrecess 32. In some useful methods, firstscleral flap 28 is secured to the remainder ofsclera 26 with a plurality of sutures. -
FIG. 18A andFIG. 18B are stylized plan views showing aneye 20. Arecess 32 has been formed ineye 20. In the embodiment ofFIG. 18A , a single aqueoushumor drainage device 122A has been advanced through afirst opening 36 defined by the wall of Schlemm's canal ofeye 20. In the embodiment ofFIG. 18B , a first aqueoushumor drainage device 122A has been advanced through afirst opening 36 defined by the wall of Schlemm's canal and a second aqueoushumor drainage device 122B has been advanced through asecond opening 38 defined by the wall of Schlemm's canal. The implants shown inFIGS. 18A and 18B may be implanted according to the methods, and using the systems, described above. -
FIG. 19A andFIG. 19B are stylized plan views showing aneye 20. Arecess 32 has been formed ineye 20. A first aqueoushumor drainage device 122 has been advanced into Schlemm's canal offirst eye 20. In the exemplary embodiment ofFIG. 19A , an inlet portion 46 of first aqueoushumor drainage device 122 has been positioned to extend into the anterior chamber AC offirst eye 20. The aqueoushumor drainage device 122 inFIG. 19B , on the other hand, lies entirely within Schlemm's canal and does not extend into the anterior chamber AC ofeye 20. Methods in accordance with this detailed description may include the step of advancing an inlet portion of a first aqueous humor drainage device into the anterior chamber of an eye. The implants shown inFIGS. 19A and 19B may be implanted according to the methods, and using the systems, described above. - The methods illustrated in
FIGS. 9-19 may be generally referred to as ab externo methods. Access to Schlemm's canal may be established using an ab interno approach or an ab externo approach. The ab externo methods described herein may be particularly useful when treating closed angle forms of glaucoma. Methods in accordance with this detailed description may include the steps of identifying a patient suffering from closed angle glaucoma and performing the method steps illustrated herein on the eye(s) of that patient. In some embodiments, a substantially straight cannula (having, e.g., a blunt distal tip) is used in connection with ab externo approaches. - FIGS. 2 and 20-22 show the use of an ab interno approach to deliver a channel tool and/or ocular implant according to embodiments of this invention.
FIG. 20A shows adistal tip 202 of adelivery system cannula 200 passing through the anterior chamber AC of an eye. In this view, the innermajor wall 252 of Schlemm's canal SC in apposition with the outermajor wall 250 preventing circumferential flow within the canal and eliminating a flow path for aqueous access with the closest collector channel. InFIG. 20B , thedistal tip 202 ofcannula 200 has passed through the trabecular meshwork TM so that at least a portion of adistal opening 204 ofcannula 200 is within Schlemm's canal SC. InFIG. 20C , achannel tool 226 is being advanced throughdistal opening 204 ofcannula 200 into Schlemm's canal to determine whether that portion of Schlemm's canal provides a suitable location for the delivery of an ocular implant and/or to open that portion of Schlemm's canal, either through the mechanical action of the advancing channel tool, via the injection of a fluid such as viscoelastic, or both.FIG. 20C includes a plurality of arrows representing fluid flowing through the side walls ofchannel tool 226. This fluid may be injected into Schlemm's canal in a series of controlled-volume increments to gently separate the walls of the canal in areas where Schlemm's canal is obstructed. Thereafter, an ocular implant (not shown) may be placed in that portion of Schlemm's canal before withdrawing thecannula 200 from Schlemm's canal, as shown inFIG. 20D .FIG. 21 shows cannula 200 entering through the cornea of the eye into the anterior chamber and Schlemm's canal. -
FIGS. 22A-F show steps of a therapy method according to this invention. InFIG. 22B , acannula 200 has been inserted through the anterior chamber of the eye to place thedistal tip 202 at least partially in Schlemm's canal SC. InFIGS. 22C and 22D , achannel tool 226 has been advanced out ofcannula 200 into Schlemm's canal SC. A fluid 228 such as viscoelastic may be ejected fromchannel tool 226 into Schlemm's canal to provide lubrication for the advancement ofchannel tool 226 and/or to dilate Schlemm's canal. Anocular implant 250 may thereafter be placed in Schlemm's canal, as shown inFIG. 22F . - In some cases, a visible colorant may be added to the viscoelastic composition. When this is the case, the visible colorant may facilitate and evaluation of canal patency. The information gained during this may assist a physician in pre-screening a patient and predicting the potential success of an aqueous drainage aqueous humor drainage device placement procedure for that patient.
-
FIG. 23A is a stylized perspective view illustrating anexemplary therapy system 3100 in accordance with this detailed description.FIG. 23B is an enlarged detail view further illustrating a portion oftherapy system 3100.FIG. 23A andFIG. 23B will be collectively referred to asFIG. 23 . Thetherapy system 3100 ofFIG. 23 includes anocular implant 3122, achannel tool 3152, apush tube 3190, acannula 3108, and afluid injection assembly 3162.Therapy system 3100 ofFIG. 23 may be used, for example, to determine whether Schlemm's canal of an eye provides a suitable location for the delivery ofocular implant 3122, to open Schlemm's canal of the eye, and/or to place an ocular implant in Schlemm's canal of the eye. - In the embodiment of
FIG. 23 ,push tube 3190 andocular implant 3122 are both disposed aboutchannel tool 3152. InFIG. 23B ,push tube 3190 can be seen extending through adistal port 3109 ofcannula 3108. A distal portion ofchannel tool 3152 can be seen extending beyondocular implant 3122 inFIG. 23A . In the embodiment ofFIG. 23 ,channel tool 3152 is slidingly disposed in lumens defined bypush tube 3190 andocular implant 3122. Accordingly,channel tool 3152 is free to translate in axial directions (e.g., distal and proximal directions) with respect to bothpush tube 3190 andocular implant 3122. This arrangement allowschannel tool 3152 to be advanced beyondocular implant 3122 and into Schlemm's canal. The distal end ofchannel tool 3152 may be advanced through a portion of Schlemm's canal, for example, to determine whether that portion of Schlemm's canal provides a suitable location for the delivery ofocular implant 3122. After making this determination, the user may advanceocular implant 3122 into the identified portion of Schlemm's canal. In the exemplary embodiment ofFIG. 23 ,ocular implant 3122 may be advanced usingpush tube 3190. - The motion of
push tube 3190 andchannel tool 3152 may be controlled using aproximal control 3102 oftherapy system 3100. In the exemplary embodiment ofFIG. 23 ,proximal control 3102 includes afirst mechanism 3166A andsecond mechanism 3166B.First mechanism 3166A is capable of advancing and retractingchannel tool 3152.Push tube 3190 may be advanced and retracted in axial directions by asecond mechanism 3166B. -
Cannula 3108 oftherapy system 3100 is adapted and configured to deliverchannel tool 3152 andocular implant 3122 into Schlemm's canal of a human eye. A number of exemplary cannulas that may be used with the therapy systems described herein are disclosed in U.S. patent application Ser. No. 12/632,738. The disclosure of this U.S. patent application is hereby incorporated by reference in its entirety. -
Ocular implant 3122 oftherapy system 3100 is adapted and configured to be disposed within Schlemm's canal of a human eye. Ocular implants that may be suitable in some applications are disclosed e.g., in U.S. Pat. No. 7,740,604; US Patent Publ. No. 2009/0082860; US Patent Publ. No. 2009/0227934; US Patent Publ. No. 2009/0132040; US Patent Publ. No. 2010/0121342; US Patent Publ. No. 2006/0195187; and U.S. application Ser. No. 12/833,863. The entire disclosure of these U.S. Patents and patent applications is hereby incorporated by reference. -
Therapy system 3100 ofFIG. 23 includes afluid injection assembly 3162.Fluid injection assembly 3162 may comprise, for example, a syringe (i.e., a piston disposed in a cylinder) that is filled with fluid.Fluid injection assembly 3162 may also include a mechanism configured to dispense a controlled volume of fluid each time an input element of the mechanism (e.g., a lever) is actuated.Fluid injection assembly 3162 fluidly communicates withchannel tool 3152 via aninjection tube 3156. -
FIG. 24 is an enlarged plan view further illustratingocular implant 3122,push tube 3190, andcannula 3108. With reference toFIG. 24 , it will be appreciated thatocular implant 3122 and pushtube 3190 are mechanically coupled to each other at aconnection 3192. In the embodiment ofFIG. 24 , an ear ofocular implant 3192 is received in an aperture defined bypush tube 3190. Additionally, an ear ofpush tube 3190 is received in an aperture defined byocular implant 3192.Channel tool 3152 extends throughconnection 3192 in the embodiment ofFIG. 24 . The presence ofchannel tool 3152 extending throughocular implant 3122 and pushtube 3190 locks these two elements together. Anarea including connection 3192 is surrounded by a frame F inFIG. 24 . This area will be enlarged for purposes of illustration in subsequent figures. -
FIG. 25A andFIG. 25B are enlarged perspective views illustrating the connection formed betweenocular implant 3122 and pushtube 3190. In the embodiment ofFIG. 25A ,ocular implant 3122 and pushtube 3190 are mechanically coupled at aconnection 3192. In the embodiment ofFIG. 25B , the connection betweenocular implant 3122 and pushtube 3190 has been broken. - As for additional details pertinent to the present invention, materials and manufacturing techniques may be employed as within the level of those with skill in the relevant art. The same may hold true with respect to method-based aspects of the invention in terms of additional acts commonly or logically employed. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Likewise, reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “and,” “said,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The breadth of the present invention is not to be limited by the subject specification, but rather only by the plain meaning of the claim terms employed.
Claims (25)
1. An ocular implant and delivery system comprising:
a channel tool adapted to extend through at least a portion of Schlemm's canal of a human eye and to determine whether the Schlemm's canal portion provides a suitable location for the delivery of an ocular implant;
an ocular implant adapted to be disposed within Schlemm's canal of a human eye; and
a cannula comprising a distal opening adapted to deliver the channel tool and the ocular implant into Schlemm's canal of the eye.
2. The system of claim 1 wherein the channel tool is further adapted to open a channel within the Schlemm's canal portion.
3. The system of claim 1 further comprising a proximal control adapted to be operated from exterior to the eye to move the channel opening tool and the ocular implant when the distal opening of the cannula is within the eye.
4. The system of claim 1 wherein the channel opening tool is configured to be disposed within the ocular implant and to move with respect to the ocular implant.
5. The system of claim 1 wherein the channel opening tool comprises a coil.
6. The system of claim 1 further comprising a fluid and a fluid injection mechanism adapted to inject the fluid into Schlemm's canal of the eye through the cannula.
7. The system of claim 6 wherein the channel opening tool comprises a fluid lumen, the fluid injection mechanism being adapted to inject fluid through the channel opening tool fluid lumen.
8. The system of claim 7 wherein the channel opening tool further comprises a distal opening communicating with the fluid lumen.
9. The system of claim 7 wherein the channel opening tool further comprises a liner tube surrounding the fluid lumen.
10. The system of claim 6 wherein the fluid injection mechanism comprises a piston disposed in a cylinder.
11. The system of claim 10 wherein the proximal control comprises a handle, the fluid injection mechanism further comprising an injection tube extending from an outlet of the cylinder to the handle.
12. The system of claim 6 wherein the fluid comprises a dilatation agent adapted to dilate tissue within the Schlemm's canal portion.
13. A method of treating glaucoma in a human eye comprising:
inserting a distal exit port of a cannula at least partially into Schlemm's canal of the eye;
delivering a channel tool through the cannula into Schlemm's canal;
delivering an ocular implant through the cannula into Schlemm's canal; and
removing the channel tool and the cannula from the eye while leaving the ocular implant in place within Schlemm's canal.
14. The method of claim 13 further comprising delivering a dye through the channel tool and observing the behavior of the dye to identify the location of obstructions within Schlemm's canal.
15. The method of claim 13 further comprising opening a channel in Schlemm's canal with the channel tool.
16. The method of claim 15 wherein the opening step comprises moving the channel tool within Schlemm's canal.
17. The method of claim 15 wherein the opening step comprises delivering a fluid through the channel tool.
18. The method of claim 17 further comprises moving the fluid through an obstruction within Schlemm's canal to increase fluid communication between adjacent segments of Schlemm's canal.
19. The method of claim 17 wherein the fluid comprises a dilatation agent adapted to dilate tissue within the Schlemm's canal portion.
20. The method of claim 17 wherein the fluid comprises a therapeutic agent.
21. The method of claim 13 wherein the delivering steps comprise delivering the channel opening tool and the ocular implant without removing the distal tip of the cannula from the eye.
22. The method of claim 13 further comprising moving the channel opening tool and the ocular implant with respect to each other within Schlemm's canal.
23. The method of claim 13 wherein the delivering steps comprise delivering the ocular implant over the channel opening tool.
24. The method of claim 13 wherein the inserting step comprises inserting the distal exit port of the cannula at least partially into Schlemm's canal of the eye through an ab interno approach.
25. The method of claim 13 wherein the inserting step comprises inserting the distal exit port of the cannula at least partially into Schlemm's canal of the eye through an ab externo approach.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/911,451 US20110098809A1 (en) | 2009-10-23 | 2010-10-25 | Ocular Implant System and Method |
US14/279,983 US9579234B2 (en) | 2009-10-23 | 2014-05-16 | Ocular implant system and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25452309P | 2009-10-23 | 2009-10-23 | |
US12/911,451 US20110098809A1 (en) | 2009-10-23 | 2010-10-25 | Ocular Implant System and Method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/279,983 Division US9579234B2 (en) | 2009-10-23 | 2014-05-16 | Ocular implant system and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110098809A1 true US20110098809A1 (en) | 2011-04-28 |
Family
ID=43899083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/911,451 Abandoned US20110098809A1 (en) | 2009-10-23 | 2010-10-25 | Ocular Implant System and Method |
US14/279,983 Active 2031-08-23 US9579234B2 (en) | 2009-10-23 | 2014-05-16 | Ocular implant system and method |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/279,983 Active 2031-08-23 US9579234B2 (en) | 2009-10-23 | 2014-05-16 | Ocular implant system and method |
Country Status (7)
Country | Link |
---|---|
US (2) | US20110098809A1 (en) |
EP (1) | EP2490621A4 (en) |
JP (1) | JP2013508096A (en) |
CN (1) | CN102647960A (en) |
AU (1) | AU2010310484A1 (en) |
CA (1) | CA2778452A1 (en) |
WO (1) | WO2011050360A1 (en) |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100191329A1 (en) * | 2006-06-26 | 2010-07-29 | Badawi David Y | Intraocular implants and methods and kits therefor |
US20110196487A1 (en) * | 2010-02-05 | 2011-08-11 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US8372026B2 (en) | 2007-09-24 | 2013-02-12 | Ivantis, Inc. | Ocular implant architectures |
US8414518B2 (en) | 2007-09-24 | 2013-04-09 | Ivantis, Inc. | Glaucoma treatment method |
WO2013096453A1 (en) | 2011-12-19 | 2013-06-27 | Ivantis, Inc. | Delivering ocular implants into the eye |
US8529494B2 (en) | 2008-03-05 | 2013-09-10 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US20130253402A1 (en) * | 2012-03-20 | 2013-09-26 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US8545430B2 (en) | 2010-06-09 | 2013-10-01 | Transcend Medical, Inc. | Expandable ocular devices |
US8551166B2 (en) | 2007-11-20 | 2013-10-08 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
WO2013158919A1 (en) | 2012-04-19 | 2013-10-24 | Transcend Medical, Inc. | Delivery system for ocular implant |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US20140155805A1 (en) * | 2012-04-24 | 2014-06-05 | Transcend Medical, Inc. | Delivery System for Ocular Implant |
WO2014085450A1 (en) * | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9039650B2 (en) | 2007-09-24 | 2015-05-26 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US9095413B2 (en) | 2011-12-08 | 2015-08-04 | Aquesys, Inc. | Intraocular shunt manufacture |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US20150297344A1 (en) * | 2014-04-21 | 2015-10-22 | Arvind Saini | Irrigating intraocular lens rotators and related methods |
US9211213B2 (en) | 2009-07-09 | 2015-12-15 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
WO2016159999A1 (en) | 2015-03-31 | 2016-10-06 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9579234B2 (en) | 2009-10-23 | 2017-02-28 | Ivantis, Inc. | Ocular implant system and method |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
WO2017106517A1 (en) * | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US10159601B2 (en) | 2000-05-19 | 2018-12-25 | Ivantis, Inc. | Delivery system and method of use for the eye |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US10492949B2 (en) | 2009-07-09 | 2019-12-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US20200378948A1 (en) * | 2018-01-05 | 2020-12-03 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
WO2021055751A1 (en) * | 2019-09-18 | 2021-03-25 | Ivantis, Inc. | Synthetic eye model for ocular implant surgical training |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
US20220218521A1 (en) * | 2021-01-11 | 2022-07-14 | Ivantis, Inc. | Systems and methods for viscoelastic delivery |
US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11744734B2 (en) | 2007-09-24 | 2023-09-05 | Alcon Inc. | Method of implanting an ocular implant |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11938059B2 (en) | 2013-11-14 | 2024-03-26 | Aquesys, Inc. | Intraocular shunt insertion techniques |
US11951037B2 (en) * | 2022-05-27 | 2024-04-09 | Sight Sciences, Inc. | Ocular delivery systems and methods |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011050164A1 (en) | 2009-10-21 | 2011-04-28 | Avedro, Inc. | Eye therapy |
EP3556330A1 (en) | 2010-03-19 | 2019-10-23 | Avedro, Inc. | Systems for applying and monitoring eye therapy |
US9044308B2 (en) | 2011-05-24 | 2015-06-02 | Avedro, Inc. | Systems and methods for reshaping an eye feature |
JP6122845B2 (en) | 2011-06-02 | 2017-04-26 | アヴェドロ・インコーポレーテッドAvedro,Inc. | System and method for monitoring the delivery of time-based photoactive agents or the presence of photoactive markers |
WO2013059837A2 (en) | 2012-07-16 | 2013-04-25 | Avedro, Inc. | Systems and methods for corneal cross-linking with pulsed light |
WO2014145684A1 (en) * | 2013-03-15 | 2014-09-18 | Avedro, Inc. | Systems and methods for treating glaucoma |
US9498122B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
US9498114B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
US10219936B2 (en) * | 2014-09-11 | 2019-03-05 | Orbit Biomedical Limited | Therapeutic agent delivery device with advanceable cannula and needle |
KR102545628B1 (en) | 2014-10-27 | 2023-06-20 | 아베드로 인코퍼레이티드 | Systems and methods for cross-linking treatments of an eye |
WO2016077747A1 (en) | 2014-11-13 | 2016-05-19 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
EP3827792A1 (en) | 2015-04-24 | 2021-06-02 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
WO2016191342A1 (en) | 2015-05-22 | 2016-12-01 | Avedro, Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
CN116832158A (en) | 2015-07-21 | 2023-10-03 | 艾维德洛公司 | Systems and methods for treating eyes with photosensitizers |
BR112019011964A2 (en) * | 2016-12-19 | 2019-11-05 | New World Medical Inc | eye care devices and related methods of use |
CN107174399B (en) * | 2017-05-27 | 2019-07-12 | 天津优视眼科技术有限公司 | What a kind of interior road was implemented applies Lai Mushi pipe operation transportation system |
EP3638164B1 (en) * | 2017-06-13 | 2023-05-10 | Innfocus, Inc. | Systems and apparatus for treatment of glaucoma |
CA3207829A1 (en) * | 2018-02-22 | 2019-08-29 | Alcon Inc. | Ocular implant and delivery system |
SG11202008901WA (en) | 2018-03-16 | 2020-10-29 | Minas Theodore Coroneo | Ophthalmic compositions, and ocular uses thereof, of indigo carmine |
WO2020086350A1 (en) * | 2018-10-24 | 2020-04-30 | New World Medical, Inc. | Ophthalmic device |
US20220151827A1 (en) * | 2019-03-15 | 2022-05-19 | Minas Theodore Coroneo | Ophthalmic Compositions, and Ocular Uses Thereof, of Indigo Carmine |
JP2022538906A (en) | 2019-07-01 | 2022-09-06 | マイケル エス. バーリン, | Image guided method and apparatus for glaucoma surgery |
Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US3811442A (en) * | 1972-03-23 | 1974-05-21 | A Maroth | Hypodermic syringe holder and applicator |
US4428746A (en) * | 1981-07-29 | 1984-01-31 | Antonio Mendez | Glaucoma treatment device |
US4722724A (en) * | 1986-06-23 | 1988-02-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4934809A (en) * | 1988-06-24 | 1990-06-19 | Volk Donald A | Lens positioning device for indirect biomicroscopy of the eye |
US4946436A (en) * | 1989-11-17 | 1990-08-07 | Smith Stewart G | Pressure-relieving device and process for implanting |
US5178604A (en) * | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5865831A (en) * | 1996-04-17 | 1999-02-02 | Premier Laser Systems, Inc. | Laser surgical procedures for treatment of glaucoma |
US6409752B1 (en) * | 1993-07-23 | 2002-06-25 | Cook Incorporated | Flexible stent having a pattern formed from a sheet of material |
US6544249B1 (en) * | 1996-11-29 | 2003-04-08 | The Lions Eye Institute Of Western Australia Incorporated | Biological microfistula tube and implantation method and apparatus |
US20040254517A1 (en) * | 2003-02-18 | 2004-12-16 | Hugo Quiroz-Mercado | Methods and devices for draining fluids and lowering intraocular pressure |
US20050041200A1 (en) * | 2001-11-07 | 2005-02-24 | Darren Rich | Gonioscopy assembly |
US20050154443A1 (en) * | 2004-01-09 | 2005-07-14 | Rubicon Medical, Inc. | Stent delivery device |
US20050260186A1 (en) * | 2003-03-05 | 2005-11-24 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20050288745A1 (en) * | 2004-06-28 | 2005-12-29 | Andersen Dan E | Method and device for optical ophthalmic therapy |
US20060178674A1 (en) * | 2005-02-08 | 2006-08-10 | Mcintyre John | Surgical apparatus having configurable portions |
US20060241749A1 (en) * | 2001-08-28 | 2006-10-26 | Hosheng Tu | Glaucoma stent system |
US20070027452A1 (en) * | 2005-05-18 | 2007-02-01 | Varner Signe E | Insertion instrument for non-linear medical devices |
US20070265582A1 (en) * | 2002-06-12 | 2007-11-15 | University Of Southern California | Injection Devices for Unimpeded Target Location Testing |
US20070293872A1 (en) * | 2006-06-20 | 2007-12-20 | Minu, L.L.C. | Ocular Drainage Device |
US20080228127A1 (en) * | 2006-11-10 | 2008-09-18 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US20090005852A1 (en) * | 1999-01-15 | 2009-01-01 | Gittings Darin C | Methods and Devices for Placing a Conduit in Fluid Communication with a Target Vessel |
US20090030381A1 (en) * | 2007-07-23 | 2009-01-29 | Lind Casey J | Arced Hypodermic Needle |
US20090030363A1 (en) * | 2002-10-30 | 2009-01-29 | Gellman Barry N | Linearly expandable ureteral stent |
US20090043321A1 (en) * | 2004-04-29 | 2009-02-12 | Iscience Interventional Corporation | Apparatus And Method For Surgical Enhancement Of Aqueous Humor Drainage |
US20090104248A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. -Qpdi | Lacrimal implants and related methods |
US20090132040A1 (en) * | 2007-11-20 | 2009-05-21 | Ivantis, Inc. | Ocular Implant Delivery System and Method |
US20090182421A1 (en) * | 2007-07-17 | 2009-07-16 | Tom Silvestrini | Ocular implant with hydrogel expansion capabilities |
US20090227934A1 (en) * | 2008-03-05 | 2009-09-10 | Euteneuer Charles L | Methods and Apparatus for Treating Glaucoma |
US20090281520A1 (en) * | 2007-11-08 | 2009-11-12 | Brian Highley | Ocular Implantation Device |
US20100004580A1 (en) * | 1999-04-26 | 2010-01-07 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US20100057072A1 (en) * | 2008-09-02 | 2010-03-04 | Medtronic, Inc. | Irrigated Ablation Catheter System and Methods |
US20100137981A1 (en) * | 2008-06-25 | 2010-06-03 | Silvestrini Thomas A | Ocular implant with shape change capabilities |
US20110196487A1 (en) * | 2010-02-05 | 2011-08-11 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US8012115B2 (en) * | 2003-02-18 | 2011-09-06 | S.K. Pharmaceuticals, Inc. | Optic nerve implants |
US20110218523A1 (en) * | 2010-03-03 | 2011-09-08 | Wavelight Ag | Apparatus for Movable and Weight-Compensating Suspension of a Focusing Objective of a Laser System |
US20120035524A1 (en) * | 2010-06-09 | 2012-02-09 | Silvestrini Thomas A | Expandable ocular devices |
US20120136439A1 (en) * | 2007-09-24 | 2012-05-31 | Schieber Andrew T | Ocular Implant Architectures |
US20120179087A1 (en) * | 2007-09-24 | 2012-07-12 | Schieber Andrew T | Glaucoma Treatment Method |
US20130267887A1 (en) * | 2010-09-21 | 2013-10-10 | The Regents Of The University Of Colorado | Aqueous humor micro-bypass shunts |
US8636647B2 (en) * | 2009-04-03 | 2014-01-28 | Transcend Medical, Inc. | Ocular implant delivery systems and methods |
Family Cites Families (224)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US703296A (en) | 1901-06-15 | 1902-06-24 | Arnold Nueesch | Cattle-probe. |
US1601709A (en) | 1924-01-28 | 1926-10-05 | Anderson Windom Edward | Retainable needle construction for syringes |
US2716983A (en) | 1952-10-08 | 1955-09-06 | Abbott Lab | Piercing needle |
US3071135A (en) | 1960-01-27 | 1963-01-01 | Mfg Process Lab Inc | Hollow needle |
US3948271A (en) | 1972-11-07 | 1976-04-06 | Taichiro Akiyama | Drain for the eardrum and apparatus for introducing the same |
US4037604A (en) | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4457757A (en) | 1981-07-20 | 1984-07-03 | Molteno Anthony C B | Device for draining aqueous humour |
US4706669A (en) | 1984-01-30 | 1987-11-17 | Schlegel Hans Joachim | Device for perforating the lens capsule front wall in the eye of living beings |
US4689040A (en) | 1985-04-29 | 1987-08-25 | Thompson Robert J | Tip for a phacoemulsification needle |
US4601713A (en) | 1985-06-11 | 1986-07-22 | Genus Catheter Technologies, Inc. | Variable diameter catheter |
US4699140A (en) | 1985-07-10 | 1987-10-13 | Iolab Corporation | Instrument for inserting an intraocular lens |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
NZ215409A (en) | 1986-03-07 | 1989-02-24 | Anthony Christopher Be Molteno | Implant for drainage of aqueous humour in glaucoma |
US4826478A (en) | 1986-06-23 | 1989-05-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4919130A (en) | 1986-11-07 | 1990-04-24 | Nestle S.A. | Tool for inserting compressible intraocular lenses into the eye and method |
US4886488A (en) | 1987-08-06 | 1989-12-12 | White Thomas C | Glaucoma drainage the lacrimal system and method |
US4880000A (en) | 1987-12-15 | 1989-11-14 | Iolab Corporation | Lens insertion instrument |
US4934363A (en) | 1987-12-15 | 1990-06-19 | Iolab Corporation | Lens insertion instrument |
US4936825A (en) | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
US4861341A (en) | 1988-07-18 | 1989-08-29 | Woodburn Robert T | Subcutaneous venous access device and needle system |
US4968296A (en) | 1989-12-20 | 1990-11-06 | Robert Ritch | Transscleral drainage implant device for the treatment of glaucoma |
US5092837A (en) | 1989-12-20 | 1992-03-03 | Robert Ritch | Method for the treatment of glaucoma |
US5180362A (en) | 1990-04-03 | 1993-01-19 | Worst J G F | Gonio seton |
US5127901A (en) | 1990-05-18 | 1992-07-07 | Odrich Ronald B | Implant with subconjunctival arch |
US5547468A (en) | 1990-07-12 | 1996-08-20 | University Of Miami | Instruments for use in performing gel injection adjustable keratoplasty |
US5290267A (en) | 1991-01-17 | 1994-03-01 | Fresenius Ag | Hypodermic needle |
US5454796A (en) | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US6007511A (en) | 1991-05-08 | 1999-12-28 | Prywes; Arnold S. | Shunt valve and therapeutic delivery system for treatment of glaucoma and methods and apparatus for its installation |
US5360399A (en) | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
US5190552A (en) | 1992-02-04 | 1993-03-02 | Kelman Charles D | Slotted tube injector for an intraocular lens |
US5213569A (en) | 1992-03-31 | 1993-05-25 | Davis Peter L | Tip for a tissue phacoemulsification device |
US5246452A (en) | 1992-04-13 | 1993-09-21 | Impra, Inc. | Vascular graft with removable sheath |
US5613972A (en) | 1992-07-15 | 1997-03-25 | The University Of Miami | Surgical cutting heads with curled cutting wings |
DE4226476C1 (en) | 1992-08-10 | 1993-08-12 | Hans Dr.Med. 3015 Wennigsen De Haindl | |
US5383926A (en) | 1992-11-23 | 1995-01-24 | Children's Medical Center Corporation | Re-expandable endoprosthesis |
US5676669A (en) | 1993-04-30 | 1997-10-14 | Colvard; Michael | Intraocular capsular shield |
US5458615A (en) | 1993-07-06 | 1995-10-17 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
US5702402A (en) | 1994-04-29 | 1997-12-30 | Allergal | Method and apparatus for folding of intraocular lens |
US5445637A (en) | 1993-12-06 | 1995-08-29 | American Cyanamid Company | Method and apparatus for preventing posterior capsular opacification |
FR2721499B1 (en) | 1994-06-22 | 1997-01-03 | Opsia | Trabeculectomy implant. |
US6102045A (en) | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
JP3573531B2 (en) | 1994-08-03 | 2004-10-06 | 鐘淵化学工業株式会社 | Microcatheter |
US5814062A (en) | 1994-12-22 | 1998-09-29 | Target Therapeutics, Inc. | Implant delivery assembly with expandable coupling/decoupling mechanism |
US5792099A (en) | 1995-02-14 | 1998-08-11 | Decamp; Dennis | Syringe and cannula for insertion of viscoelastic material into an eye and method of using same |
US5575780A (en) | 1995-04-28 | 1996-11-19 | Saito; Yoshikuni | Medical hollow needle and a method of producing thereof |
US5626558A (en) | 1995-05-05 | 1997-05-06 | Suson; John | Adjustable flow rate glaucoma shunt and method of using same |
IL113723A (en) | 1995-05-14 | 2002-11-10 | Optonol Ltd | Intraocular implant |
US5968058A (en) | 1996-03-27 | 1999-10-19 | Optonol Ltd. | Device for and method of implanting an intraocular implant |
US5536259A (en) | 1995-07-28 | 1996-07-16 | Medisystems Technology Corp | Hypodermic cannula |
US5807302A (en) | 1996-04-01 | 1998-09-15 | Wandel; Thaddeus | Treatment of glaucoma |
US5948427A (en) | 1996-04-25 | 1999-09-07 | Point Medical Corporation | Microparticulate surgical adhesive |
US6328747B1 (en) | 1996-05-09 | 2001-12-11 | Itos Innovative Technology In Ocular Surgery, Ltd. | Method and a system for performing cataract surgery |
EP0906063A1 (en) | 1996-05-09 | 1999-04-07 | Itos, Innovative Technology in Ocular Surgery Ltd. | A method and a system for performing cataract surgery |
GB9700390D0 (en) | 1997-01-10 | 1997-02-26 | Biocompatibles Ltd | Device for use in the eye |
US5893837A (en) | 1997-02-28 | 1999-04-13 | Staar Surgical Company, Inc. | Glaucoma drain implanting device and method |
US5911732A (en) | 1997-03-10 | 1999-06-15 | Johnson & Johnson Interventional Systems, Co. | Articulated expandable intraluminal stent |
US6050970A (en) | 1997-05-08 | 2000-04-18 | Pharmacia & Upjohn Company | Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye |
EP0898947A3 (en) | 1997-08-15 | 1999-09-08 | GRIESHABER & CO. AG SCHAFFHAUSEN | Method and apparatus to improve the outflow of the aqueous humor of an eye |
US6591838B2 (en) | 1998-07-06 | 2003-07-15 | Scimed Life Systems, Inc. | Implant system and method for bulking tissue |
AU5339099A (en) | 1998-08-05 | 2000-02-28 | Keravision, Inc. | Corneal implant with migration preventer |
DE19840047B4 (en) | 1998-09-02 | 2004-07-08 | Neuhann, Thomas, Prof.Dr.med. | Device for the targeted improvement and / or permanent guarantee of the permeability for eye chamber water through the trabecular mechanism in the Schlemm's Canal |
US6241721B1 (en) * | 1998-10-09 | 2001-06-05 | Colette Cozean | Laser surgical procedures for treatment of glaucoma |
US6447520B1 (en) | 2001-03-19 | 2002-09-10 | Advanced Medical Optics, Inc. | IOL insertion apparatus with IOL engagement structure and method for using same |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
DE60018710T2 (en) | 1999-02-04 | 2006-04-13 | Integ Inc., St. Paul | NEEDLE FOR BODY FLUID TEST SET |
JP3492543B2 (en) | 1999-03-15 | 2004-02-03 | 金子工業有限会社 | Injection needle and its manufacturing method |
US7214229B2 (en) | 1999-03-18 | 2007-05-08 | Fossa Medical, Inc. | Radially expanding stents |
US20050119601A9 (en) | 1999-04-26 | 2005-06-02 | Lynch Mary G. | Shunt device and method for treating glaucoma |
US6699210B2 (en) | 1999-04-27 | 2004-03-02 | The Arizona Board Of Regents | Glaucoma shunt and a method of making and surgically implanting the same |
CA2372149A1 (en) | 1999-05-03 | 2000-11-09 | Dean F. Carson | Methods and devices for placing a conduit in fluid communication with a target vessel |
US6858034B1 (en) | 1999-05-20 | 2005-02-22 | Scimed Life Systems, Inc. | Stent delivery system for prevention of kinking, and method of loading and using same |
US6221078B1 (en) | 1999-06-25 | 2001-04-24 | Stephen S. Bylsma | Surgical implantation apparatus |
US8500795B2 (en) | 1999-08-09 | 2013-08-06 | Cardiokinetix, Inc. | Retrievable devices for improving cardiac function |
JP4085351B2 (en) | 1999-09-14 | 2008-05-14 | ドクタージャパン株式会社 | Epidural anesthesia needle |
KR100771149B1 (en) | 1999-12-10 | 2007-10-30 | 아이싸이언스 인터벤셔날 코포레이션 | Treatment of ocular disease |
US20090028953A1 (en) * | 1999-12-10 | 2009-01-29 | Yamamoto Ronald K | Method of treatment using microparticulate biomaterial composition |
US6726676B2 (en) | 2000-01-05 | 2004-04-27 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving the flow of aqueous humor within the eye |
US6375642B1 (en) | 2000-02-15 | 2002-04-23 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving a drainage of aqueous humor within the eye |
US6471666B1 (en) | 2000-02-24 | 2002-10-29 | Steven A. Odrich | Injectable glaucoma device |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US6533768B1 (en) | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US20040111050A1 (en) | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US20050277864A1 (en) | 2000-04-14 | 2005-12-15 | David Haffner | Injectable gel implant for glaucoma treatment |
US20020143284A1 (en) | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US20030060752A1 (en) | 2000-04-14 | 2003-03-27 | Olav Bergheim | Glaucoma device and methods thereof |
US20050049578A1 (en) | 2000-04-14 | 2005-03-03 | Hosheng Tu | Implantable ocular pump to reduce intraocular pressure |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
ES2295169T3 (en) | 2000-05-19 | 2008-04-16 | Michael S. Berlin | LASER ADMINISTRATION SYSTEM AND EYE USE PROCEDURE. |
JP3364654B2 (en) | 2000-05-31 | 2003-01-08 | 独立行政法人産業技術総合研究所 | Virtual form generation apparatus and generation method |
US6394979B1 (en) | 2000-06-09 | 2002-05-28 | Inviro Medical Devices Ltd. | Cannula for use with a medical syringe |
CA2407953A1 (en) | 2000-06-19 | 2001-12-27 | Glaukos Corporation | Stented trabecular shunt and methods thereof |
USD444874S1 (en) | 2000-07-31 | 2001-07-10 | Allergan Sales, Inc. | Self instill twist housing eye drop dispenser |
US6699211B2 (en) | 2000-08-22 | 2004-03-02 | James A. Savage | Method and apparatus for treatment of glaucoma |
US6730056B1 (en) | 2000-09-21 | 2004-05-04 | Motorola, Inc. | Eye implant for treating glaucoma and method for manufacturing same |
US6962573B1 (en) | 2000-10-18 | 2005-11-08 | Wilcox Michael J | C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use |
WO2002036052A1 (en) | 2000-11-01 | 2002-05-10 | Glaukos Corporation | Glaucoma treatment device |
US6533764B1 (en) | 2000-11-06 | 2003-03-18 | Allergan, Inc. | Twist housing apparatus for instilling a medication into an eye |
US6544208B2 (en) | 2000-12-29 | 2003-04-08 | C. Ross Ethier | Implantable shunt device |
US6881198B2 (en) | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
MXPA03006394A (en) | 2001-01-18 | 2003-10-15 | Univ California | Minimally invasive glaucoma surgical instrument and method. |
US6692524B2 (en) | 2001-01-19 | 2004-02-17 | Georges Baikoff | Techniques and implants for correcting presbyopia |
US6989007B2 (en) | 2001-02-21 | 2006-01-24 | Solx, Inc. | Devices and techniques for treating glaucoma |
WO2002074052A2 (en) | 2001-03-16 | 2002-09-26 | Glaukos Corporation | Applicator and methods for placing a trabecular shunt for glaucoma treatment |
JP3310270B1 (en) | 2001-03-28 | 2002-08-05 | 宮子 鎌田 | Medical injection needle and method of manufacturing the same |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
US7488303B1 (en) * | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US6981958B1 (en) | 2001-05-02 | 2006-01-03 | Glaukos Corporation | Implant with pressure sensor for glaucoma treatment |
WO2002080811A2 (en) | 2001-04-07 | 2002-10-17 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
AT409586B (en) | 2001-04-26 | 2002-09-25 | Clemens Dr Vass | Implant draining aqueous humor from anterior chamber of eye into Schlemm's channel, includes fixation plate for stabilization on sclera |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
WO2002089699A2 (en) | 2001-05-03 | 2002-11-14 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US6802827B2 (en) | 2001-06-26 | 2004-10-12 | Stig O. Andersson | Hypodermic implant device |
US8267995B2 (en) | 2001-08-03 | 2012-09-18 | David Castillejos | Method and intra sclera implant for treatment of glaucoma and presbyopia |
RU2004107571A (en) | 2001-08-16 | 2004-11-10 | Джи Эм Пи ВИЖН СОЛЮШНЗ, ИНК. (US) | ADVANCED BYPASS DEVICE AND GLAUCOMA TREATMENT METHOD |
US20030097151A1 (en) | 2001-10-25 | 2003-05-22 | Smedley Gregory T. | Apparatus and mitochondrial treatment for glaucoma |
US7163543B2 (en) | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20030093084A1 (en) | 2001-11-13 | 2003-05-15 | Optonol Ltd. | Delivery devices for flow regulating implants |
AU2002365403B2 (en) | 2001-11-21 | 2009-07-09 | Iscience Interventional Corporation | Ophthalmic microsurgical system |
US6770093B2 (en) | 2002-01-23 | 2004-08-03 | Ophtec B.V. | Fixation of an intraocular implant to the iris |
US6939298B2 (en) * | 2002-02-28 | 2005-09-06 | Gmp Vision Solutions, Inc | Device and method for monitoring aqueous flow within the eye |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
US20060200113A1 (en) | 2002-03-07 | 2006-09-07 | David Haffner | Liquid jet for glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20030229303A1 (en) | 2002-03-22 | 2003-12-11 | Haffner David S. | Expandable glaucoma implant and methods of use |
US20040147870A1 (en) | 2002-04-08 | 2004-07-29 | Burns Thomas W. | Glaucoma treatment kit |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US20040024345A1 (en) | 2002-04-19 | 2004-02-05 | Morteza Gharib | Glaucoma implant with valveless flow bias |
AU2003233300A1 (en) | 2002-05-29 | 2003-12-12 | University Of Saskatchewan Technologies Inc. | A shunt and method treatment of glaucoma |
US20030236483A1 (en) | 2002-06-25 | 2003-12-25 | Ren David H | Dual drainage ocular shunt for glaucoma |
WO2004006774A2 (en) | 2002-07-12 | 2004-01-22 | Iscience Surgical Corporation | Ultrasound interfacing device for tissue imaging |
EP2286773B1 (en) | 2002-07-19 | 2012-10-17 | Yale University | Uveoscleral drainage device |
US7175660B2 (en) | 2002-08-29 | 2007-02-13 | Mitralsolutions, Inc. | Apparatus for implanting surgical devices for controlling the internal circumference of an anatomic orifice or lumen |
US7192412B1 (en) | 2002-09-14 | 2007-03-20 | Glaukos Corporation | Targeted stent placement and multi-stent therapy |
EP1539066B1 (en) | 2002-09-17 | 2012-11-07 | Iscience Surgical Corporation | Apparatus surgical bypass of aqueous humor |
US20050203542A1 (en) | 2002-09-18 | 2005-09-15 | Allergan, Inc. | Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events |
MXPA05002841A (en) | 2002-09-18 | 2005-05-27 | Oculex Pharm Inc | Methods and apparatus for delivery of ocular implants. |
US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
AU2003290881A1 (en) | 2002-11-15 | 2004-06-15 | Gmp Cardiac Care, Inc. | Rail stent |
US20040098124A1 (en) | 2002-11-19 | 2004-05-20 | Freeman Jerre M. | Elongate scleral implants for the treatment of eye disorders such as presbyopia and glaucoma |
JPWO2004054643A1 (en) | 2002-12-13 | 2006-04-20 | テルモ株式会社 | Medical needle body and liquid guide |
US20040122380A1 (en) | 2002-12-19 | 2004-06-24 | Utterberg David S. | Blunt cannula with bent tip |
JP5148107B2 (en) | 2003-01-21 | 2013-02-20 | カルメル ファルマ アクチボラゲット | Needle for piercing the membrane |
AT413332B (en) | 2003-01-23 | 2006-02-15 | Clemens Dr Vass | DRAINAGE IMPLANT FOR THE DISPOSAL OF CHAMBER WATER FROM THE FRONT EYE CHAMBER IN THE EPISCLERAL VEINS |
US20040216749A1 (en) | 2003-01-23 | 2004-11-04 | Hosheng Tu | Vasomodulation during glaucoma surgery |
USD490152S1 (en) | 2003-02-28 | 2004-05-18 | Glaukos Corporation | Surgical handpiece |
US20040193095A1 (en) | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US20040193262A1 (en) | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US20040199171A1 (en) | 2003-04-04 | 2004-10-07 | Takayuki Akahoshi | Phacoemulsification needle |
ATE439107T1 (en) | 2003-04-16 | 2009-08-15 | Iscience Interventional Corp | MICROSURGICAL INSTRUMENTS FOR OPHTHALMOLOGY |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
WO2004110391A2 (en) | 2003-06-16 | 2004-12-23 | Solx, Inc. | Shunt for the treatment of glaucoma |
US20060069340A1 (en) | 2003-06-16 | 2006-03-30 | Solx, Inc. | Shunt for the treatment of glaucoma |
US7147650B2 (en) | 2003-10-30 | 2006-12-12 | Woojin Lee | Surgical instrument |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US7431709B2 (en) | 2003-12-05 | 2008-10-07 | Innfocus, Llc | Glaucoma implant device |
US6929664B2 (en) | 2003-12-05 | 2005-08-16 | Fossa Medical, Inc. | Open lumen stents |
CN101912325A (en) | 2004-01-12 | 2010-12-15 | i科学外科公司 | Injector for viscous materials |
CA2554165A1 (en) | 2004-01-22 | 2005-08-11 | Solx, Inc. | Glaucoma treatment method |
DK1715827T3 (en) | 2004-01-23 | 2011-04-18 | Iscience Interventional Corp | Compound ophthalmic micro cannula |
US20050250788A1 (en) * | 2004-01-30 | 2005-11-10 | Hosheng Tu | Aqueous outflow enhancement with vasodilated aqueous cavity |
US7468051B2 (en) | 2004-03-02 | 2008-12-23 | Boston Scientific Scimed, Inc. | Occlusion balloon catheter with external inflation lumen |
JP2007534383A (en) | 2004-04-23 | 2007-11-29 | ジーエムピー ヴィジョン ソルーションズ インコーポレイテッド | Indwelling shunt device and device and method for glaucoma |
US20100173866A1 (en) | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
CN101052434A (en) | 2004-04-29 | 2007-10-10 | I科学干预公司 | Apparatus and method for ocular treatment |
US20080058704A1 (en) | 2004-04-29 | 2008-03-06 | Michael Hee | Apparatus and Method for Ocular Treatment |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
EP1750595A4 (en) | 2004-05-07 | 2008-10-22 | Valentx Inc | Devices and methods for attaching an endolumenal gastrointestinal implant |
US20060032507A1 (en) | 2004-08-11 | 2006-02-16 | Hosheng Tu | Contrast-enhanced ocular imaging |
US20060173397A1 (en) | 2004-11-23 | 2006-08-03 | Hosheng Tu | Ophthalmology implants and methods of manufacture |
CA2592459C (en) | 2004-12-16 | 2017-08-22 | Iscience Interventional Corporation | Ophthalmic implant for treatment of glaucoma |
US20120010702A1 (en) | 2004-12-16 | 2012-01-12 | Iscience Interventional Corporation | Ophthalmic implant for treatment of glaucoma |
US20060154981A1 (en) | 2005-01-12 | 2006-07-13 | Alcon, Inc. | Method of reducing intraocular pressure and treating glaucoma |
US20060167466A1 (en) | 2005-01-21 | 2006-07-27 | Vaclav Dusek | Intraocular lens inserter system components |
US20060167421A1 (en) | 2005-01-21 | 2006-07-27 | Radius International Ltd. Partnership | Catheter with insert-molded tip |
AR054647A1 (en) | 2005-02-21 | 2007-07-11 | Maldonado Bas Arturo | DEVICE FOR WATER HUMOR DRAINAGE IN GLAUCOMA CASES |
US7641627B2 (en) | 2005-02-23 | 2010-01-05 | Camras Carl B | Method and apparatus for reducing intraocular pressure |
US20060217741A1 (en) | 2005-03-28 | 2006-09-28 | Ghannoum Ziad R | Irrigation tip |
US20060264971A1 (en) | 2005-05-18 | 2006-11-23 | Takayuki Akahoshi | Intraocular lens injection nozzle |
US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
EP1924306A2 (en) | 2005-09-16 | 2008-05-28 | BG Implant, Inc. | Glaucoma treatment devices and methods |
US8496628B2 (en) | 2005-09-30 | 2013-07-30 | Erskine Medical Llc | Needle-based medical device including needle guide |
AU2006304553A1 (en) | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Method for treating primary and secondary forms of glaucoma |
US20070106200A1 (en) | 2005-11-08 | 2007-05-10 | Brian Levy | Intraocular shunt device and method |
US8251963B2 (en) | 2005-12-08 | 2012-08-28 | Boston Scientific Scimed, Inc. | Flexible needle |
ES2551782T3 (en) | 2006-01-17 | 2015-11-23 | Transcend Medical, Inc. | Device for the treatment of glaucoma |
US7942894B2 (en) | 2006-01-31 | 2011-05-17 | Codman & Shurtleff, Inc. | Embolic device delivery system |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
JP2007244671A (en) | 2006-03-16 | 2007-09-27 | Fujifilm Corp | Blood collecting needle, injection needle, winged needle, test kit and blood collection kit |
US20070293807A1 (en) | 2006-05-01 | 2007-12-20 | Lynch Mary G | Dual drainage pathway shunt device and method for treating glaucoma |
EP2123239B1 (en) | 2006-05-18 | 2012-03-21 | STAAR Japan Inc. | Insertion device for intraocular lens |
US7909789B2 (en) * | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US20080108933A1 (en) | 2006-06-30 | 2008-05-08 | Dao-Yi Yu | Methods, Systems and Apparatus for Relieving Pressure in an Organ |
KR20090102810A (en) | 2006-12-26 | 2009-09-30 | 큐엘티 플러그 딜리버리, 인코포레이티드 | Drug delivery implants for inhibition of optical defects |
US8956419B2 (en) | 2007-05-14 | 2015-02-17 | Boston Scientific Scimed, Inc. | Open lumen stent |
US20080312661A1 (en) | 2007-06-12 | 2008-12-18 | Downer David A | Lens Injector Lumen Tip for Wound Assisted Delivery |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
WO2009048523A1 (en) | 2007-10-12 | 2009-04-16 | Medical Research Products-B, Inc. | Medical apparatus and method for facilitating the management of long term tunneled conduits |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8088150B2 (en) | 2008-02-04 | 2012-01-03 | Aleeva Medical Inc. | Device for disc shunt implantation and peri-shunt injection |
US8109896B2 (en) | 2008-02-11 | 2012-02-07 | Optonol Ltd. | Devices and methods for opening fluid passageways |
EP2262555A2 (en) | 2008-03-27 | 2010-12-22 | iScience Interventional Corporation | Microliter injector |
AU2009231645A1 (en) | 2008-04-02 | 2009-10-08 | Laurimed, Llc | Methods and devices for delivering injections |
WO2010065970A1 (en) | 2008-12-05 | 2010-06-10 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
CH700161A2 (en) | 2008-12-22 | 2010-06-30 | Grieshaber Ophthalmic Res Foun | IMPLANT FOR INTRODUCING into Schlemm's canal AN EYE. |
US20100191177A1 (en) | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
JP5524983B2 (en) | 2009-01-28 | 2014-06-18 | トランセンド・メディカル・インコーポレイテッド | Implant system |
CA2762071A1 (en) | 2009-05-15 | 2010-11-18 | Iscience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
AU2010271274B2 (en) | 2009-07-09 | 2015-05-21 | Alcon Inc. | Single operator device for delivering an ocular implant |
JP5635605B2 (en) | 2009-07-09 | 2014-12-03 | イバンティス インコーポレイテッド | Intraocular implant and method for delivering an intraocular implant into an eyeball |
US8951221B2 (en) | 2009-08-20 | 2015-02-10 | Grieshaber Ophthalmic Research Foundation | Method and device for the treatment of glaucoma |
WO2011050360A1 (en) | 2009-10-23 | 2011-04-28 | Ivantis, Inc. | Ocular implant system and method |
WO2011057283A1 (en) | 2009-11-09 | 2011-05-12 | Iscience Interventional Corporation | Expandable cannula for infusion of fluids |
WO2011106781A1 (en) | 2010-02-26 | 2011-09-01 | Iscience Interventional Corporation | Apparatus for enhancement of aqueous humor drainage from the eye |
BR112012030160B1 (en) | 2010-05-27 | 2020-11-03 | Iscience Interventional Corporation | tool and device for total circumferential insertion for an implant in the schlemm canal of the eye |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
CN106214321B (en) | 2010-10-15 | 2018-08-28 | 科尼尔赛德生物医学公司 | Device for entering eyes |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
CN106073986B (en) | 2011-09-14 | 2019-01-11 | 弗赛特影像5股份有限公司 | The device for treating the eyes of patient |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US20130182223A1 (en) | 2012-01-17 | 2013-07-18 | John Wardle | Suspended goniolens system |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
-
2010
- 2010-10-25 WO PCT/US2010/053957 patent/WO2011050360A1/en active Application Filing
- 2010-10-25 AU AU2010310484A patent/AU2010310484A1/en not_active Abandoned
- 2010-10-25 EP EP10825808A patent/EP2490621A4/en not_active Withdrawn
- 2010-10-25 CA CA2778452A patent/CA2778452A1/en not_active Abandoned
- 2010-10-25 CN CN2010800565115A patent/CN102647960A/en active Pending
- 2010-10-25 US US12/911,451 patent/US20110098809A1/en not_active Abandoned
- 2010-10-25 JP JP2012535443A patent/JP2013508096A/en active Pending
-
2014
- 2014-05-16 US US14/279,983 patent/US9579234B2/en active Active
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US3811442A (en) * | 1972-03-23 | 1974-05-21 | A Maroth | Hypodermic syringe holder and applicator |
US4428746A (en) * | 1981-07-29 | 1984-01-31 | Antonio Mendez | Glaucoma treatment device |
US4722724A (en) * | 1986-06-23 | 1988-02-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4934809A (en) * | 1988-06-24 | 1990-06-19 | Volk Donald A | Lens positioning device for indirect biomicroscopy of the eye |
US4946436A (en) * | 1989-11-17 | 1990-08-07 | Smith Stewart G | Pressure-relieving device and process for implanting |
US5178604A (en) * | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US6409752B1 (en) * | 1993-07-23 | 2002-06-25 | Cook Incorporated | Flexible stent having a pattern formed from a sheet of material |
US5865831A (en) * | 1996-04-17 | 1999-02-02 | Premier Laser Systems, Inc. | Laser surgical procedures for treatment of glaucoma |
US6544249B1 (en) * | 1996-11-29 | 2003-04-08 | The Lions Eye Institute Of Western Australia Incorporated | Biological microfistula tube and implantation method and apparatus |
US20090005852A1 (en) * | 1999-01-15 | 2009-01-01 | Gittings Darin C | Methods and Devices for Placing a Conduit in Fluid Communication with a Target Vessel |
US20100004580A1 (en) * | 1999-04-26 | 2010-01-07 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US20060241749A1 (en) * | 2001-08-28 | 2006-10-26 | Hosheng Tu | Glaucoma stent system |
US20050041200A1 (en) * | 2001-11-07 | 2005-02-24 | Darren Rich | Gonioscopy assembly |
US20070265582A1 (en) * | 2002-06-12 | 2007-11-15 | University Of Southern California | Injection Devices for Unimpeded Target Location Testing |
US20090030363A1 (en) * | 2002-10-30 | 2009-01-29 | Gellman Barry N | Linearly expandable ureteral stent |
US20040254517A1 (en) * | 2003-02-18 | 2004-12-16 | Hugo Quiroz-Mercado | Methods and devices for draining fluids and lowering intraocular pressure |
US8012115B2 (en) * | 2003-02-18 | 2011-09-06 | S.K. Pharmaceuticals, Inc. | Optic nerve implants |
US20050260186A1 (en) * | 2003-03-05 | 2005-11-24 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20050154443A1 (en) * | 2004-01-09 | 2005-07-14 | Rubicon Medical, Inc. | Stent delivery device |
US20090043321A1 (en) * | 2004-04-29 | 2009-02-12 | Iscience Interventional Corporation | Apparatus And Method For Surgical Enhancement Of Aqueous Humor Drainage |
US20050288745A1 (en) * | 2004-06-28 | 2005-12-29 | Andersen Dan E | Method and device for optical ophthalmic therapy |
US20060178674A1 (en) * | 2005-02-08 | 2006-08-10 | Mcintyre John | Surgical apparatus having configurable portions |
US20070027452A1 (en) * | 2005-05-18 | 2007-02-01 | Varner Signe E | Insertion instrument for non-linear medical devices |
US20070293872A1 (en) * | 2006-06-20 | 2007-12-20 | Minu, L.L.C. | Ocular Drainage Device |
US20080228127A1 (en) * | 2006-11-10 | 2008-09-18 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US20090182421A1 (en) * | 2007-07-17 | 2009-07-16 | Tom Silvestrini | Ocular implant with hydrogel expansion capabilities |
US20090030381A1 (en) * | 2007-07-23 | 2009-01-29 | Lind Casey J | Arced Hypodermic Needle |
US20090104248A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. -Qpdi | Lacrimal implants and related methods |
US20120179087A1 (en) * | 2007-09-24 | 2012-07-12 | Schieber Andrew T | Glaucoma Treatment Method |
US20120136439A1 (en) * | 2007-09-24 | 2012-05-31 | Schieber Andrew T | Ocular Implant Architectures |
US20090281520A1 (en) * | 2007-11-08 | 2009-11-12 | Brian Highley | Ocular Implantation Device |
US20090132040A1 (en) * | 2007-11-20 | 2009-05-21 | Ivantis, Inc. | Ocular Implant Delivery System and Method |
US20090227934A1 (en) * | 2008-03-05 | 2009-09-10 | Euteneuer Charles L | Methods and Apparatus for Treating Glaucoma |
US20100137981A1 (en) * | 2008-06-25 | 2010-06-03 | Silvestrini Thomas A | Ocular implant with shape change capabilities |
US20100057072A1 (en) * | 2008-09-02 | 2010-03-04 | Medtronic, Inc. | Irrigated Ablation Catheter System and Methods |
US8636647B2 (en) * | 2009-04-03 | 2014-01-28 | Transcend Medical, Inc. | Ocular implant delivery systems and methods |
US20110196487A1 (en) * | 2010-02-05 | 2011-08-11 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US20110218523A1 (en) * | 2010-03-03 | 2011-09-08 | Wavelight Ag | Apparatus for Movable and Weight-Compensating Suspension of a Focusing Objective of a Laser System |
US20120035524A1 (en) * | 2010-06-09 | 2012-02-09 | Silvestrini Thomas A | Expandable ocular devices |
US20130267887A1 (en) * | 2010-09-21 | 2013-10-10 | The Regents Of The University Of Colorado | Aqueous humor micro-bypass shunts |
Cited By (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
US9827143B2 (en) | 1999-04-26 | 2017-11-28 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10492950B2 (en) | 1999-04-26 | 2019-12-03 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
US10390993B1 (en) | 2000-05-19 | 2019-08-27 | Ivantis, Inc. | Delivery system and method of use for the eye |
US10687978B2 (en) | 2000-05-19 | 2020-06-23 | Ivantis, Inc. | Delivery system and method of use for the eye |
US10159601B2 (en) | 2000-05-19 | 2018-12-25 | Ivantis, Inc. | Delivery system and method of use for the eye |
US10335314B2 (en) | 2000-05-19 | 2019-07-02 | Ivantis, Inc. | Delivery system and method of use for the eye |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US9370443B2 (en) | 2006-06-26 | 2016-06-21 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US20100191329A1 (en) * | 2006-06-26 | 2010-07-29 | Badawi David Y | Intraocular implants and methods and kits therefor |
US10398597B2 (en) | 2006-06-26 | 2019-09-03 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US8287482B2 (en) | 2006-06-26 | 2012-10-16 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US9486361B2 (en) | 2006-06-26 | 2016-11-08 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US11389328B2 (en) | 2006-06-26 | 2022-07-19 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US20110130831A1 (en) * | 2006-06-26 | 2011-06-02 | Badawi David Y | Intraocular implants and methods and kits therefor |
US11865041B2 (en) | 2006-06-26 | 2024-01-09 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US10314742B2 (en) | 2006-06-26 | 2019-06-11 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US11744734B2 (en) | 2007-09-24 | 2023-09-05 | Alcon Inc. | Method of implanting an ocular implant |
US9039650B2 (en) | 2007-09-24 | 2015-05-26 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US9610196B2 (en) | 2007-09-24 | 2017-04-04 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US8961447B2 (en) | 2007-09-24 | 2015-02-24 | Ivantis, Inc. | Glaucoma treatment method |
US8372026B2 (en) | 2007-09-24 | 2013-02-12 | Ivantis, Inc. | Ocular implant architectures |
US9402767B2 (en) | 2007-09-24 | 2016-08-02 | Ivantis, Inc. | Ocular implant architectures |
US8414518B2 (en) | 2007-09-24 | 2013-04-09 | Ivantis, Inc. | Glaucoma treatment method |
US9050169B2 (en) | 2007-11-20 | 2015-06-09 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9226852B2 (en) | 2007-11-20 | 2016-01-05 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8551166B2 (en) | 2007-11-20 | 2013-10-08 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9351874B2 (en) | 2007-11-20 | 2016-05-31 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9693902B2 (en) | 2008-03-05 | 2017-07-04 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US8529494B2 (en) | 2008-03-05 | 2013-09-10 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US10537474B2 (en) | 2008-03-05 | 2020-01-21 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US9066783B2 (en) | 2008-03-05 | 2015-06-30 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US11344448B2 (en) | 2009-01-28 | 2022-05-31 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US11839571B2 (en) | 2009-01-28 | 2023-12-12 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US10531983B2 (en) | 2009-01-28 | 2020-01-14 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9211213B2 (en) | 2009-07-09 | 2015-12-15 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US11918514B2 (en) | 2009-07-09 | 2024-03-05 | Alcon Inc. | Single operator device for delivering an ocular implant |
US11596546B2 (en) | 2009-07-09 | 2023-03-07 | Alcon Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US10492949B2 (en) | 2009-07-09 | 2019-12-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US10406025B2 (en) | 2009-07-09 | 2019-09-10 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US11464675B2 (en) | 2009-07-09 | 2022-10-11 | Alcon Inc. | Single operator device for delivering an ocular implant |
US9579234B2 (en) | 2009-10-23 | 2017-02-28 | Ivantis, Inc. | Ocular implant system and method |
US11166847B2 (en) | 2010-02-05 | 2021-11-09 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US8439972B2 (en) | 2010-02-05 | 2013-05-14 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US8529622B2 (en) | 2010-02-05 | 2013-09-10 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US10406030B2 (en) | 2010-02-05 | 2019-09-10 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US20110196487A1 (en) * | 2010-02-05 | 2011-08-11 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US8876898B2 (en) | 2010-02-05 | 2014-11-04 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US8545430B2 (en) | 2010-06-09 | 2013-10-01 | Transcend Medical, Inc. | Expandable ocular devices |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US10363168B2 (en) | 2011-06-14 | 2019-07-30 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US9155655B2 (en) | 2011-06-14 | 2015-10-13 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US9095413B2 (en) | 2011-12-08 | 2015-08-04 | Aquesys, Inc. | Intraocular shunt manufacture |
US9592154B2 (en) | 2011-12-08 | 2017-03-14 | Aquesys, Inc. | Intraocular shunt manufacture |
US9113994B2 (en) | 2011-12-08 | 2015-08-25 | Aquesys, Inc. | Intraocular shunt manufacture |
US10314743B2 (en) | 2011-12-08 | 2019-06-11 | Aquesys, Inc. | Intraocular shunt manufacture |
EP2763625A1 (en) * | 2011-12-19 | 2014-08-13 | Ivantis, Inc. | Delivering ocular implants into the eye |
US20150119787A1 (en) * | 2011-12-19 | 2015-04-30 | John Wardle | Delivering ocular implants into the eye |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US11135088B2 (en) | 2011-12-19 | 2021-10-05 | Ivantis Inc. | Delivering ocular implants into the eye |
EP2763625A4 (en) * | 2011-12-19 | 2014-10-08 | Ivantis Inc | Delivering ocular implants into the eye |
US9931243B2 (en) * | 2011-12-19 | 2018-04-03 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9066750B2 (en) | 2011-12-19 | 2015-06-30 | Ivantis, Inc. | Delivering ocular implants into the eye |
WO2013096453A1 (en) | 2011-12-19 | 2013-06-27 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9855167B2 (en) * | 2012-03-20 | 2018-01-02 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11471324B2 (en) * | 2012-03-20 | 2022-10-18 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20230233372A1 (en) * | 2012-03-20 | 2023-07-27 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9895258B2 (en) | 2012-03-20 | 2018-02-20 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20230277373A1 (en) * | 2012-03-20 | 2023-09-07 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11344447B2 (en) * | 2012-03-20 | 2022-05-31 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11116660B2 (en) * | 2012-03-20 | 2021-09-14 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10179066B2 (en) * | 2012-03-20 | 2019-01-15 | Sight Sciences, Inc. | Ocular delivery systems and methods |
EP4302734A3 (en) * | 2012-03-20 | 2024-03-20 | Sight Sciences, Inc. | Ocular delivery systems and methods |
AU2020202716B2 (en) * | 2012-03-20 | 2021-04-15 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10888453B2 (en) * | 2012-03-20 | 2021-01-12 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10857027B2 (en) | 2012-03-20 | 2020-12-08 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20230233371A1 (en) * | 2012-03-20 | 2023-07-27 | Sight Sciences, Inc. | Ocular delivery systems and methods |
AU2012374034B2 (en) * | 2012-03-20 | 2017-10-19 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US8894603B2 (en) | 2012-03-20 | 2014-11-25 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20150335481A1 (en) * | 2012-03-20 | 2015-11-26 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11389327B2 (en) * | 2012-03-20 | 2022-07-19 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20220280340A1 (en) * | 2012-03-20 | 2022-09-08 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20220280339A1 (en) * | 2012-03-20 | 2022-09-08 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9216109B2 (en) * | 2012-03-20 | 2015-12-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20130253437A1 (en) * | 2012-03-20 | 2013-09-26 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20130253402A1 (en) * | 2012-03-20 | 2013-09-26 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20180271699A1 (en) * | 2012-03-20 | 2018-09-27 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9095412B2 (en) * | 2012-03-20 | 2015-08-04 | Sight Sciences, Inc. | Ocular delivery systems and methods |
EP3047823A1 (en) * | 2012-03-20 | 2016-07-27 | Sight Sciences, Inc. | Ocular delivery systems |
EP2844200A4 (en) * | 2012-03-20 | 2016-04-27 | Sight Sciences Inc | Ocular delivery systems and methods |
US20160100980A1 (en) * | 2012-03-20 | 2016-04-14 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11617679B2 (en) * | 2012-03-20 | 2023-04-04 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11944573B2 (en) | 2012-03-26 | 2024-04-02 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11197780B2 (en) | 2012-03-26 | 2021-12-14 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11026836B2 (en) | 2012-04-18 | 2021-06-08 | Ivantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
EP2838470A4 (en) * | 2012-04-19 | 2015-11-25 | Transcend Medical Inc | Delivery system for ocular implant |
EP3730103A1 (en) * | 2012-04-19 | 2020-10-28 | Alcon Inc. | Delivery system for ocular implant |
AU2013249153B2 (en) * | 2012-04-19 | 2017-02-02 | Alcon Inc. | Delivery system for ocular implant |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
CN104540472A (en) * | 2012-04-19 | 2015-04-22 | 创森德医疗设备公司 | Delivery system for ocular implant |
JP2015516858A (en) * | 2012-04-19 | 2015-06-18 | トランセンド・メディカル・インコーポレイテッドTranscend Medical, Inc. | Delivery system for intraocular implants |
RU2636859C2 (en) * | 2012-04-19 | 2017-11-28 | Новартис Аг | System of eye implant delivery |
WO2013158919A1 (en) | 2012-04-19 | 2013-10-24 | Transcend Medical, Inc. | Delivery system for ocular implant |
EP3403622A1 (en) * | 2012-04-19 | 2018-11-21 | Novartis Ag | Delivery system for ocular implant |
US9907697B2 (en) | 2012-04-24 | 2018-03-06 | Novartis Ag | Delivery system for ocular implant |
US9155656B2 (en) * | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US20140155805A1 (en) * | 2012-04-24 | 2014-06-05 | Transcend Medical, Inc. | Delivery System for Ocular Implant |
US10912676B2 (en) | 2012-04-24 | 2021-02-09 | Alcon Inc. | Delivery system for ocular implant |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
WO2014085450A1 (en) * | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US11712369B2 (en) | 2012-11-28 | 2023-08-01 | Alcon Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US10195079B2 (en) | 2013-02-19 | 2019-02-05 | Aquesys, Inc. | Adjustable intraocular implant |
US10195078B2 (en) | 2013-02-19 | 2019-02-05 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US10188551B2 (en) | 2013-03-15 | 2019-01-29 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11523938B2 (en) | 2013-03-15 | 2022-12-13 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11559430B2 (en) | 2013-03-15 | 2023-01-24 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US11938059B2 (en) | 2013-11-14 | 2024-03-26 | Aquesys, Inc. | Intraocular shunt insertion techniques |
US20150297344A1 (en) * | 2014-04-21 | 2015-10-22 | Arvind Saini | Irrigating intraocular lens rotators and related methods |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US11872158B2 (en) | 2015-03-31 | 2024-01-16 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
WO2016159999A1 (en) | 2015-03-31 | 2016-10-06 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11090188B2 (en) | 2015-03-31 | 2021-08-17 | Sight Sciences, Inc. | Ocular delivery systems and methods |
CN113208806A (en) * | 2015-03-31 | 2021-08-06 | 美国商业眼科医疗器械公司 | Ophthalmic delivery systems and methods |
EP3277236A4 (en) * | 2015-03-31 | 2018-12-19 | Sight Sciences, Inc. | Ocular delivery systems and methods |
EP3964183A1 (en) * | 2015-03-31 | 2022-03-09 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
WO2017106517A1 (en) * | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
USD901683S1 (en) | 2017-10-27 | 2020-11-10 | Glaukos Corporation | Implant delivery apparatus |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
USD938585S1 (en) | 2017-10-27 | 2021-12-14 | Glaukos Corporation | Implant delivery apparatus |
US20200378948A1 (en) * | 2018-01-05 | 2020-12-03 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
WO2021055751A1 (en) * | 2019-09-18 | 2021-03-25 | Ivantis, Inc. | Synthetic eye model for ocular implant surgical training |
US11857460B2 (en) | 2019-09-27 | 2024-01-02 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20220218521A1 (en) * | 2021-01-11 | 2022-07-14 | Ivantis, Inc. | Systems and methods for viscoelastic delivery |
US11540940B2 (en) * | 2021-01-11 | 2023-01-03 | Alcon Inc. | Systems and methods for viscoelastic delivery |
US11951037B2 (en) * | 2022-05-27 | 2024-04-09 | Sight Sciences, Inc. | Ocular delivery systems and methods |
Also Published As
Publication number | Publication date |
---|---|
EP2490621A4 (en) | 2013-04-03 |
CN102647960A (en) | 2012-08-22 |
AU2010310484A1 (en) | 2012-05-10 |
US9579234B2 (en) | 2017-02-28 |
CA2778452A1 (en) | 2011-04-28 |
WO2011050360A1 (en) | 2011-04-28 |
EP2490621A1 (en) | 2012-08-29 |
US20140249463A1 (en) | 2014-09-04 |
JP2013508096A (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9579234B2 (en) | Ocular implant system and method | |
US20230107345A1 (en) | Methods and apparatus for treating glaucoma | |
US20190343679A1 (en) | Ocular implants and methods for delivering ocular implants into the eye | |
AU2009322146B2 (en) | Methods and apparatus for delivering ocular implants into the eye | |
US9351874B2 (en) | Methods and apparatus for delivering ocular implants into the eye | |
AU2015218475B2 (en) | Methods and apparatus for delivering ocular implants into the eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IVANTIS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WARDLE, JOHN;SCHIEBER, ANDREW T.;GALT, KENNETH M.;REEL/FRAME:026388/0796 Effective date: 20101025 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ALCON INC., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IVANTIS, INC.;REEL/FRAME:061161/0697 Effective date: 20220719 |